

## CURRICULUM VITAE

January 12, 2020

**Name:** J. Silvio Gutkind

**Work Address:** University of California San Diego  
Moore's Cancer Center  
3855 Health Sciences Drive MC0803, Room 2344  
La Jolla, CA 92093  
Tel: +1 (858) 534-5980  
E-mail: sgutkind@ucsd.edu

### Education:

1976-1980 Pharmacy Degree (M.Sc.), University of Buenos Aires, Argentina  
1976-1983 Biochemistry Degree (M.Sc.), University of Buenos Aires, Argentina.  
1985 Ph.D. in Pharmacy and Biochemistry, University of Buenos Aires, Argentina

### Employment History:

2019-Present Distinguished Professor, Department of Pharmacology, School of Medicine, University of California San Diego (UCSD), USA  
2015-Present Associate Director of Basic Science, Moore's Cancer Center, and Co-Director, Head and Neck Cancer Center  
2015-2019 Professor, Department of Pharmacology, School of Medicine, University of California San Diego (UCSD), USA  
1998-2015 Chief, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, USA  
1997-2015 Chief, Cell Growth Regulation Section and Molecular Carcinogenesis Unit, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, USA  
1996-1997 Acting Chief, Oral and Pharyngeal Cancer Branch, National Institute of Dental Research, NIH, Bethesda, USA  
1993-1997 Chief, Molecular Signaling Unit, Laboratory of Cellular Development and Oncology, National Institute of Dental Research, NIH, Bethesda, USA  
1992-1993 Head, Molecular Signaling Group, Laboratory of Cellular Development and Oncology, National Institute of Dental Research, NIH, Bethesda, USA  
1989-1992 Visiting Associate, Laboratory of Cellular Development and Oncology, National Institute of Dental Research, NIH, Bethesda, USA  
1988-1989 Fogarty Visiting Fellow, Laboratory of Cellular Development and Oncology, National Institute of Dental Research, NIH, Bethesda, USA  
1987-1988 Fogarty Visiting Fellow, NIDR, Guest Researcher at the Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH, Bethesda, USA  
1986-1987 International Fogarty Fellow, Laboratory of Clinical Science, National Institute of Mental Health, NIH, Bethesda, USA  
1983-1986 Research Assistant, Department of Pharmacology, School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina  
1981-1983 Part-time Instructor, Department of Pharmacology, School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina

1979-1980 Part-time Instructor, Department of Organic Chemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina

### Honors and Awards:

2020 Certificate of recognition, United States Senate, for outstanding contributions to to the advancement of medical sciences, health care, and public health.

2019 Elected, National Academy of Medicine (NAM), USA  
Elected Chair, Division of Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics (ASPET)  
Elected Co-Chair, Gordon Conference in Molecular Pharmacology, Ventura CA

2017 International Association of Dental Research (IADR), Distinguished Scientist Award  
Keynote Lecture, ASPET 2017, Division for Molecular Pharmacology  
Postdoctoral Scientist Award

2015 Pharmaceutical Research and Manufacturers of America (PhRMA), 2015 Research & Hope Award for "Excellence in Academic Research", for the seminal work on GPCR Function in Cancer  
Keynote Lecture, ASPET Upstate New York Pharmacology Society 4th Annual Meeting, Rochester, NY

2014 Keynote Lecture, 2014 American Head and Neck Society (AHNS) Annual Meeting and 5th World Congress-IFHNOS  
Distinguished Lecture Series at Massachusetts Eye and Ear Infirmary/Schepens Eye Research Institute, Harvard University, MA  
Keynote Speaker, Dental Research in Review, University of North Carolina, Chapel Hill, NC  
Keynote Speaker, Fifth Annual Cancer Biology Research Retreat, University of Maryland-Baltimore

2013 PABMB (Pan-American Association for Biochemistry and Molecular Biology)  
Plenary Lecture, Madrid, Spain  
Elected, Keynote Lecture, 2014 American Head and Neck Society (AHNS) Annual Meeting and 5th World Congress-IFHNOS  
Elected, Councilor, Basic Research, International Academy/Association of Oral Oncology (IAOO)  
International Keynote speaker at the Weizmann-Brazil Signal Transduction meeting, "Novel Angiogenic and Antiangiogenic Signaling Circuitries", The Weizmann Institute of Science, Israel  
Honorary Professor, West China School of Stomatology, Sichuan University, Chengdu, China

2012 Elliot Osserman Award, Israel Cancer Research Foundation

2011 Raices Award, Ministry of Science, Presidency of Argentina, for scientific contributions and efforts in enhancing research training and technology development, Argentina.  
Keynote Speaker, (IADR, Chile) Asociación Internacional de Investigación Dental – División Chile, Chile  
Keynote Speaker, NCI Frederick Spring Research Festival, Frederick, MD  
Visiting Professor, Georgetown University, Washington DC

2010 Visiting Professor and Clinical Ground Round Speaker, Memorial Sloan Kettering Cancer Center, New York, NY  
Keynote Speaker, 6th Annual International Head and Neck Symposium, Los Angeles, CA, July 2010

- Honorary Professor, University of Buenos Aires, Argentina  
 Keynote Speaker, The First South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2010, Cordoba, Argentina
- 2009 Keynote Lecture, Symposium on Molecular Medicine, Virginia Commonwealth University, Richmond, VA  
 Keynote Speaker, School of Dentistry University of Michigan Research Day, Ann Arbor, MI  
 Keynote speaker at the Annual Meeting of the Chilean Society of Biochemistry and Molecular Biology, Concepcion, Chile  
 Keynote Inaugural Lecture, Annual meeting of the Argentine Society of Research in Biochemistry and Molecular Biology, Tucuman, Argentina
- 2008 Hyman Niznik Memorial Keynote Lectureship, Annual Joint Meeting of the Great Lakes: G Protein-Coupled Receptor Retreat, Bromont, Canada  
 Merk Frosst Lecture, Institut de Recherches Cliniques de Montreal (IRCM), Montreal, Canada  
 R.M. Tiwari Oration, National Conference, Foundation for Head and Neck Oncology, Bhubaneswar, India
- 2007 Frank Brook Memorial Lecture, American Pancreatic Association, Chicago, IL
- 2006 Elected, Co-chair, Gordon Research Conference, "Phosphorylation & G-Protein Mediated Signaling Networks", 2008
- 2006 Miguel Aleman Lecture, Miguel Aleman Foundation, Mexico DF, Mexico
- 2005 NIH Director's Award
- 2005 Elliot Osserman Award, Israel Cancer Research Foundation
- 2004 International Association of Dental Research (IADR) Distinguished Scientist Award, Oral Medicine and Pathology
- 2003 NIH Hispanic Heritage Month Celebration: Hispanic Contributions to Research in the United States, Lecture
- 2000 NIDCR Director's Exemplary Service Award
- 1999 EEO Special Achievement Award, NIDCR, NIH
- 1998 Appointment as member of the Senior Biomedical Research Services (SBRS)
- 1997 NIDR Director's Exemplary Service Award
- 1996 NIH Merit Award
- 1989 Funds for Young Scientists, Travel Award, Organizing Committee of the 7th International Conference on Protein Phosphorylation, Kobe, Japan
- 1986 International Fogarty Fellowship, National Institutes of Health, USA
- 1983 Gold Medal Award and Diploma of Honor, first rank student of the School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina.

#### **Editorial Responsibilities:**

- 1998-2003 Member, Editorial Board, Journal of Biological Chemistry
- 1998-2000 Editor, Book on Signaling Networks and Cell Cycle Control, Humana Press
- 2000-2003 Co-Editor, Book on Head and Neck Cancer, Emerging Perspectives, Wiley & Co
- 2000-2016 Member, Editorial Board, Oral Oncology
- 2001-2011 Member, Editorial Board, Biochemistry
- 2001-2006 Member, Editorial Board, Revista de Oncologia, Mexico-Spain
- 2002-2003 Co-Editor, Book on Signal Transduction and Human Disease, Wiley & Co
- 2002-2017 Member, Faculty 1000, Reviewing Editor
- 2003-2005 Member, Editorial Board, Drug Discovery Today: Disease Mechanisms
- 2005-2019 Member, Editorial Board, Molecular Biology of the Cell
- 2008-present Member, Editorial Board, Cancer Prevention Research

2009-2019 Member, Editorial Board, Molecular and Cellular Biology  
 2009-2015 Member, Editorial Board, Genes & Cancer  
 2010-2014 Member, Editorial Board, Journal of Biological Chemistry  
 2012-present Member, Editorial Board, Science Signaling  
 2013 Co-editor, Current Opinion in Cell Biology, Cell Regulation Issue, April 2013  
 2015-present Member, Editorial Advisory Board for Molecular Pharmacology  
 2017-2018 Co-Editor, Journal of Dental Research, Oral Cancer Special Issue

**Ad-hoc Reviewer:**

Biochemical and Biophysical Acta; Blood; British Journal of Cancer; Cancer Cell; Cancer Research; Clinical Cancer Research; Cell; Cell Stem Cell; Cell Growth and Differentiation; Clinical Cancer Research; Current Biology; Developmental Cell; EMBO Journal; FEBS letters; Journal of Biological Chemistry; Journal of Cell Biology; Journal of Cell Physiology; Journal of Clinical Investigation; Journal of Immunology; Journal of Neurochemistry; Molecular and Cellular Biology; Molecular and Cellular Neurobiology; Molecular Cell; Molecular Pharmacology; Nature; Nature Cell Biology; Nature Communications; Nature Genetics; Nature Medicine; Oncogene; Oral Oncology; Trends in Biological Science; Proceedings of the National Academy of Science, USA; Science, Science Signaling, Science Translational Medicine

**Membership and Activity in Professional Societies:**

Executive Committee Member, and Elected Chair, Division of Molecular Pharmacology, American Society for Pharmacology and Experimental Therapeutics (ASPET)  
 American Association of Cancer Research (AACR)  
 American Society for Biochemistry and Molecular Biology (ASBMB)  
 International Association for Dental Research (IADR)  
 American Association for Dental Research (AADR)  
 Founding Member, International Academy of Oral Oncology (IAOO)

**Extramural Activities:**

**NIH Extramural**

1997 Ad-hoc member, Program Project Review Panel, DER, NCI  
 1999-2000 Member, Grant Review Panel, Division of Basic Science, NCI  
 2002 Ad-hoc Member, NIH Study Section, CDF-4  
 2002 Co-chair, FY2004 NIDCR Initiatives, Head and Neck Cancer, Molecular Anatomy of Head and Neck Cancer: A Genomic/Proteomic Approach  
 2003-2004 Member AIDS Malignancies Consortium, NIH  
 2003 Member, Biological Pathways and Networks Group, NIH Road Map Initiative  
 2004-2007 Member, NIH extramural Study Section, NDT  
 2005 Member, NIGMS, Special Emphasis Review Panel  
 2005 Member, Review Panel NRSA-NIH, Fellowships: Molecular and Cellular Mechanisms  
 2007 Ad-hoc Member, NIH extramural Study Section, Intercellular Interactions (ICI)  
 2008 Ad-hoc Member, NIH extramural Study Section, Tumor Microenvironment (TME)  
 Ad-hoc Member, NIH extramural Study Section, Molecular and Integrative Signal Transduction (MIST)  
 2008-2012 Member, NIH extramural Study Section, Tumor Microenvironment (TME)

2009 Member, NIH extramural Study Section, NIH Challenge Grants in Health and Science Research, American Recovery and Reinvestment Act of 2009

2010 Site Visit Review Panel, Laboratory of Biochemistry, Office of Biotechnology Products, Center for Biologics Evaluation and Research, FDA

2012 Reviewer, NIH extramural Study Section, Center for Scientific Review Special Emphasis Panel, Cancer Biology -2

2012 Reviewer, PREVENT Cancer Preclinical Drug Development Program, NCI

2013 Reviewer, NIH extramural Study Section, NCI Omnibus R03/R21 Grant Application Review, Cancer Biology-2

2013 Reviewer, NIH extramural Study Section, Special Emphasis Panel/Scientific Review Group Basic Translational (OBT)

2014 Participant, Center for Scientific Review's Pilot Study, evaluation of relative quality of grant applications, NIH

2014 Reviewer, NIH/NCI extramural Study Section, Center for Scientific Review Special Emphasis Panel/Scientific Review Group ZCA1 SRB-C R

2014 Reviewer, PREVENT Cancer Preclinical Drug Development Program, NCI

2015 Reviewer, NCI Outstanding Investigator Award (OIA)

2016 Reviewer, NIH Study Section, Basic Mechanisms of Cancer Therapeutics (BMCT)

2016 Reviewer, PREVENT Cancer Preclinical Drug Development Program, NCI

2016 Reviewer, NCI Special Emphasis Panel, PROGRAM PROJECT III (P01)

2017 Reviewer, NIH Study Section, Basic Mechanisms of Cancer Therapeutics (BMCT)

2017-2023 Member, NIH Study Section, Mechanisms of Cancer Therapeutics (MCT1)

### International

1996-present Reviewer, The Israel Science Foundation

1997-present Reviewer, Italian Association for Scientific Research

1997-2002 Reviewer, German-Israeli Foundation for Scientific Research & Development

1997-2006 Reviewer, National Science Foundation

1998-2001 Member, Cancer Genome Anatomy Program

1998-2004 Member, Reviewing Council, FONCYT, Argentina

2003-2005 Member Reviewing Panel, The Israel Cancer Research Foundation

2008-2017 Member Scientific Advisory Board, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany, Germany

2009 Review Panel, Regional Collaborative Program SFB/TR23, Vascular Differentiation, and Remodeling, Mannheim, Germany

2010-2017 Comité Científico Asesor Externo de la Red Temática de Investigación Cooperativa en Cáncer (RTICC), Spain

2010-2012 Member Reviewing Panel, The Israel Cancer Research Foundation

2013 Review Panel, Regional Collaborative Program SFB/TR23, Vascular Differentiation, and Remodeling, Mannheim, Germany

2013 Site Visit Review, Foundation Leloir Institute, Buenos Aires, Argentina

2015 Site Visit Review, Life Sciences Center, McGill University, Montreal, Canada

2016 Site Visit Review, Foundation Leloir Institute, Buenos Aires, Argentina

2018 Review Panel, Collaborative Research Centre (CRC) 1366 "Vascular Control of Organ function", Mannheim, Germany

### **Selected NIH Intramural Activities outside the NIDCR**

1998-2000 Chair, Head and Neck Cancer Consortium, NIH  
1998-2001 Member, NIH Central Tenure Committee  
2001-2004 Member, Steering Committee, NIH-NCI Upper Aerodigestive Track Cancer Intramural Faculty  
2003-2015 Member, NIDCD, Title 42 Standing Committee  
2007 Member, Member, Search Committee, Scientific Director of the Center for Cancer Research, NCI  
2011 Chair, Cancer Biology Search Committee, NIH Stadtman Investigator  
2013 Representative, Office of the NIH Director, Tenure Committee, 3 Tenure Track reviews, NCI  
2014 Member, NIDCR NIH Intramural Research Program (IRP) Review Group, a Vision for the IRP 2014  
2014 Representative, Office of the NIH Director, Tenure Committee, 3 Tenure Track reviews, NCI  
2019 Board of Scientific Counselors (BSC) for the Division of Intramural Research (DIR) in the National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD

### **Selected Activities within NIH NIDCR**

1995-1997 Member, Gene Targeting Facility Oversight Committee, NIDR  
1995-1996 Member, Sequencing Core Facility Oversight Committee, NIDR  
1997-2006 Member, NIDCR Administrative Oversight Committee  
1997-2006 Member, NIDCR Tenure and Promotion Committee  
2006-2015 Co-chair, Craniofacial Tissue Remodeling Initiative, NIDCR  
2011 Organizing Committee, Workshop on salivary Gland Tumor Research: Current Status and Future Directions, Bethesda  
2014 Member, NIDCR NIH Intramural Research Program (IRP) Review Group, a Vision for the IRP 2014

### **Invited Presentations (past 10 years and planned)**

2020- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, upcoming  
The 11th Weinman Symposium, University of Hawaii Cancer Center, Honolulu, Hawaii  
Feist-Weiller Cancer Center Spring Seminar Series, Shreveport, LA  
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, upcoming  
NCI Distinguished Investigator Series, NIH, Bethesda, MD, upcoming  
Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, upcoming  
Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, upcoming  
UCSF Program in Craniofacial Biology Seminar Series, San Francisco, CA, upcoming  
Gordon Research Conference on Phosphorylation and G protein Mediated Signaling Networks, Waterville Valley Resort, NH, upcoming  
FASEB Meeting - The GRK and Arrestins Conference: Key Modulation of GPCR Signal Transduction, Lisbon, Portugal, upcoming

AHNS 10<sup>th</sup> International Conference on Head and Neck Cancer, Chicago, IL, upcoming  
 Fanconi Anemia Research Fund 2020 symposium, Austin, TX, upcoming  
 46<sup>th</sup> La Jolla Immunology Conference, Salk Institute, La Jolla, CA, upcoming  
 8<sup>th</sup> International Conference on Hippo Signalling in Development, Disease and New Therapies, National University of Singapore, upcoming  
 2019- Keynote, German PharmTox Summit, Stuttgart, Germany  
 Purdue University NCI Cancer Center, West Lafayette, IN  
 Experimental Biology Symposium, Orlando, FL  
 AACR Special Conference on "The Hippo Pathway, Signaling, Cancer, and Beyond", San Diego, CA  
 IADR Presidential Symposium, Vancouver, Canada  
 AACR Think Tank on Combination Therapies, Washington DC  
 Molecular Therapeutics of Cancer Center Conference, Tahoe resort, CA  
 International Symposium on Pharmacology of 7TM-receptors and downstream signaling, UCSD  
 Signaling Pathways, University of Bonn, Germany  
 UT Health School of Dentistry, Houston, TX  
 Baylor College of Medicine, Houston, TX  
 Boston University, Boston, MA  
 NYU Langone Health, Perlmutter NCI-Designated Comprehensive Cancer Center, New York, NY  
 2018- Tohoku University Cancer Symposium, Sendai, Japan  
 Keystone Meeting on GPCRs. Santa Fe, NM  
 Pathology Research Seminar Series at the Weill Cornell Medical College, NYC  
 AACR Annual Meeting, Chicago, IL  
 Experimental Biology Meeting, San Diego, CA  
 Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA  
 Gordon Research Conference on "Phosphorylation and G-Protein Mediated Signaling Networks", University of New England, Biddeford, ME  
 3<sup>rd</sup> New Horizons in Immunotherapy and Head and Neck Cancer, Pittsburgh, PA  
 NIH Head & Neck/Thyroid SPORE Workshop, Rockville, MD  
 AACR-LACOG Translational Cancer Medicine Conference, Sao Paulo, Brazil  
 Fourth South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2018, Bariloche, Argentina  
 9<sup>th</sup> Xiamen Winter Symposium on the Hippo Signaling in Development & Disease, Xiamen, China  
 British Pharmacological Society-Molecular Pharmacology of GPCRs meeting, Monash University, Parkville, Victoria, Australia  
 2017- Keynote Speaker, 9th ÖGMBT Annual Meeting & 8th Life Science Meeting, Innsbruck, Austria  
 Stanley S. Scott Cancer Center Invited Speaker Series, New Orleans, LA  
 Loma Linda University, Loma Linda, CA  
 IADR, International Association of Dental Research Annual Meeting, San Francisco, CA  
 Symposium: "12 years SFB-TR23: From Vascular Differentiation and Remodeling to Organotypic Vasculature", Heidelberg, Germany  
 AACR-Head and Neck Cancer Meeting, San Diego, CA  
 G Protein Coupled Receptor Meeting, Boon, Germany  
 VanTol symposium at the 18th annual joint meeting of the Great Lakes GPCR Retreat, Ottawa, Canada

- 2016- UCSF Helen Diller Comprehensive Cancer Center Director's Seminar Series, San Francisco, CA  
 Cancer Prevention Summit, American Association of Cancer Research (AACR), Leesburg, VA  
 The Salk Post-Translational Regulation of Cell Signaling Meeting, La Jolla, CA  
 Gordon Research Conference, Phosphorylation & G-Protein Mediated Signaling Networks, Biddeford, Maine  
 MedImmune, Gaithersburg, MD  
 3rd Annual Meeting of the International Ovarian in conjunction with International Symposium on Tumor Microenvironment & Therapy Resistance, Oklahoma City, OK  
 International Symposium ROOTS Program, Winning The War Against Cancer, Buenos Aires, Argentina  
 AAAS Annual Meeting. Session on Oral Cancer Epidemiology, Mechanism, and Early detection. Washington DC  
 Global Cancer Forum, New York City, NY  
 Experimental Biology, ASPET Symposium on GPCR signaling through Rho GTPases, San Diego, CA  
 Society of Clinical Investigation & Society of Pharmacology, joint Annual Meeting. Mar Del Plata, Argentina.
- 2015- Bioquant and University of Heidelberg, Heidelberg, Germany  
 American Association of Cancer Research (AACR), Philadelphia, PA  
 American Society of Clinical Oncology (ASCO), Chicago, IL  
 Cancer Prevention Think Tank, National Cancer Institute, Bethesda, MD  
 Keynote Lecture, ASPET Upstate New York Pharmacology Society 4th Annual Meeting, Rochester, NY  
 UNC Lineberger Comprehensive Cancer Center's Seminar Series, University of North Carolina (UNC), Chapel Hill, NC  
 The Second South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2015, Argentina  
 The Dean's Biomedical Research Seminar, Virginia Commonwealth University, Richmond, VA  
 University of Virginia, Charlottesville, VA  
 University of California Los Angeles (UCLA), Vascular Biology Lecture, LA, CA  
 UCSD Moores Cancer Center, San Diego, CA  
 Gordon Research Conference, "Molecular Pharmacology", Ventura, CA
- 2014- Great Lakes GPCR Retreat, Bromont, Canada, upcoming.  
 Keynote Lecture, 2014 American Head and Neck Society (AHNS) Annual Meeting and 5th World Congress-IFHNOS  
 Clinical Grand Rounds, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX  
 UCSD Moores Cancer Center, San Diego, CA  
 Keynote Speaker, Dental Research in Review, University of North Carolina, Chapel Hill, NC  
 Distinguished Lecture Series at Massachusetts Eye and Ear Infirmary/Schepens Eye Research Institute, Harvard University, MA  
 Mini-Symposium, Cancer Biology, Medical School, University of Chile, Chile  
 Summer Course, Cancer Biology: From Basic to Clinic, University of Concepcion, Chile  
 IVMB, The 18<sup>th</sup> International Vascular Biology Meeting, Kyoto, Japan  
 West China School of Stomatology, Sichuan University, Chengdu, China

Leuven University, Leuven, Belgium  
 Maastricht University, Netherlands  
 2013- University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA  
 The Weizmann Institute of Science, Israel  
 PABMB (Pan-American Association for Biochemistry and Molecular Biology)  
 Plenary Lecture, Madrid, Spain  
 Annual Meeting, American Society for Biochemistry and Molecular Biology,  
 ASBMB, Boston, MA  
 West China School of Stomatology, Sichuan University, Chengdu, China  
 GPCR Workshop, Maui, Hawaii  
 UC Berkeley, San Francisco, CA  
 Ocular Melanoma Workshop, Melanoma Society, Philadelphia, PA  
 2012- Keystone Meeting, G Protein-Coupled Receptors: Molecular Mechanisms and  
 Novel Functional Insights, Alberta, Canada  
 NIH 2012 Demystifying Medicine Course, NIH, Bethesda, MD  
 Gordon Research Conference, Phosphorylation & G-Protein Mediated Signaling  
 Networks, Biddeford, Maine  
 First Symposium on Head and Neck Cancer Stem Cells, Ann Arbor, MI  
 8th International Conference on Head & Neck Cancer, Toronto  
 NIH Clinical Center Grand Rounds  
 The Second South American Spring Symposium in Signal Transduction and  
 Molecular Medicine, SISTAM 2012, Argentina  
 University of Sydney, Sydney, Australia  
 Australian Health & Medical Research Congress, Adelaide, Australia  
 2011- IMCB Institute of Molecular and Cellular Biology, Singapore  
 Institute for Cancer Research and Treatment, University of Torino, Torino, Italy  
 University of Illinois College of Medicine, Chicago, IL  
 AACR 102 Annual Meeting, Orlando, FL  
 MinnCResT Symposium: Head & Neck Cancer, University of Minnesota,  
 Minneapolis, MN  
 Boston University, Department of Molecular and cellular Biology, Boston, MA  
 Yale University, Department of Pharmacology, New Haven, CT  
 Third Meeting, International Association of Oral Oncology (IAOO), Singapore  
 IADR Annual Meeting, Stem Cells, Reprogramming, Immunomodulation and  
 Cancer session, San Diego, CA  
 IADR Annual Meeting, Stem Cells, New Targets for the Prevention and  
 Treatment of Oral and Head and Neck Cancer session, San Diego, March 2011  
 Keynote Speaker, (IADR, Chile) Asociación Internacional de Investigación Dental  
 – División Chile, Chile  
 Cell Signaling Networks, Merida, Yucatan, Mexico  
 Vascular Differentiation and Remodeling Meeting, Schloss Mannheim, Germany  
 Keynote Speaker, NCI Frederick Spring Research Festival, Frederick, MD  
 Visiting Professor, Georgetown University, Washington DC  
 2010- Moores UCSD Cancer Center, Director's Seminar Series, UCSD, CA  
 University of Buenos Aires, Buenos Aires, Argentina  
 Keynote Speaker, The First South American Spring Symposium in Signal  
 Transduction and Molecular Medicine, SISTAM 2010, Cordoba, Argentina  
 IBYME, Buenos Aires, Argentina  
 Basic Science Speaker, 92<sup>nd</sup> Annual Meeting, American Association of Oral and  
 Maxillofacial Surgeons (AAOMS), Chicago, IL

Visiting Professor and Clinical Ground Round Speaker, Memorial Sloan Kettering  
 Cancer Center, New York, NY  
 University of Cincinnati, Cincinnati, OH  
 AACR 101st Annual Meeting, Washington, DC  
 Fudan University, Shanghai, China  
 2009- Keynote Speaker, U. Michigan School of Dentistry Research Day, Ann Arbor, MI  
 Symposium on "The Origin of Cancer", Van Andel Institute, Grand Rapids, MI  
 Keynote Lecture, Symposium on Molecular Medicine, Virginia Commonwealth  
 University, Richmond, VA  
 Keynote Speaker, Annual Meeting of the Argentinean Society for Biochemistry, n  
 Tucuman, Argentina  
 Keystone Symposia: Angiogenesis and Lymphangiogenesis in Cancer, Big Sky,  
 MT  
 FASEB Symposium on Lipid Signaling, Session Chair and Lecture, Carefree, AZ  
 Van Andel Institute, Origins of Cancer Symposium, Grand Rapids, MI  
 University of Maryland, Baltimore, MD  
 University of North Carolina, Chapel Hill, NC  
 University of Pittsburgh, Pittsburgh, PA  
 University of Chicago Cancer Research Center, Chicago, IL  
 Louisiana State University, Head and Neck Surgical Oncology Feist-Weiller  
 Cancer Center, Shreveport, LA  
 ASPET's Experimental Biology 2009 Symposia on Virally-encoded G-Protein  
 Coupled Receptors as New Drug Targets, New Orleans, LA  
 Gordon Research Conference, "Molecular Pharmacology", Il Ciocco, Italy  
 Unidad de Biología Celular Centro Nacional de Microbiología, Instituto de Salud  
 Carlos III, Madrid, Spain  
 Centro de Investigación del Cáncer IBMSS, Salamanca, Spain

### **Symposia Organized:**

1995 Workshop on Signaling through G proteins, NIH  
 1996 Workshop on Signal Transduction from the Membrane to the Nucleus, NIH  
 1996 Third Annual Signal Transduction Therapy Conference, San Diego, California  
 1996 Symposium on Regulation of Protein Kinases Involved in Cell Division, Congress  
 of the Pan American Association of Biochemistry and Molecular Biology, Pucon,  
 Chile  
 1998 Workshop on G proteins, 10th International Conference on Second Messengers  
 & Phosphoproteins, Jerusalem, Israel  
 1999 Workshop on "Head and Neck Cancer Priority Setting", organizing committee,  
 NIH  
 1999 Keystone Winter Symposia, "Oncogene Networks" and Session on "Cell Surface  
 Receptors"  
 2002 Workshop on Exchange factors, Juan March Foundation, Madrid, Spain  
 2002 Symposium, Frontiers in Molecular Mechanisms in Cancer, Strategies and  
 Application, Santander, Spain  
 2002 NCI, NIDCD, NIDCR, Trans-NIH Squamous Carcinogenesis Retreat  
 2002 International Oral Cancer Tissue Array Initiative, Organizing Meeting, NIDCR  
 2004 Tva-Animal Models Meeting, Bethesda, MD  
 2005 Advisory Organizing Committee, 10<sup>th</sup> International Congress on Oral Cancer  
 (ICOOC), Crete, Greece  
 2006 "Oral Cancer", Naresuan University, Phitsanulok, Thailand

- 2006 Organizing Committee, "Workshop on Biology and Treatment of Malignant Salivary Gland Cancers", NIH, Bethesda, MD
- 2006 Elected, Co-chair, Gordon Research Conference, "Phosphorylation & G-Protein Mediated Signaling Networks", 2008
- 2007 Advisory Committee, International Association of Oral Oncology, 1st World Congress, Amsterdam
- 2008 Co-chair, Gordon Research Conference, "Phosphorylation & G-Protein Mediated Signaling Networks", Biddeford, Maine
- 2008 Organizing Committee, International Conference on Frontiers of Dental and Craniofacial Research, Beijing, China.
- 2008 Program Committee, 7<sup>th</sup> International Conference on Head and Neck Cancer, San Francisco, CA.
- 2008 Program Committee, Workshop on Salivary Gland Tumor Research: Current Status and Future Directions. Bethesda, MD.
- 2009 Scientific Advisory Committee, International Oral Oncology Meeting, Toronto, Canada.
- 2010 Co-Organizer, The First South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2010, Cordoba, Argentina
- 2011 Scientific Advisory Committee, Cell Signaling Networks 2011, Merida, Yucatan, Mexico
- 2012 Program Organizing Committee, Workshop on salivary Gland Tumor Research: Current Status and Future Directions, Bethesda
- 2012 Co-Organizer, The Second South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2012, Argentina
- 2015 Co-Organizer, The Third South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2015, Argentina
- 2016 Co-Organizer, Global Cancer Forum, New York City, NY, 2016
- 2016 Co-organizer, Symposium on Cancer Stem Cells as Pharmacological Targets, ASPET/EB Annual Meeting, San Diego, 2016
- 2017 Co-Organizer, AACR-AHNS Conference on Head and Neck Cancer, San Diego, CA
- 2017 Organizer, Moores Cancer Center Science Retreat, La Jolla, CA
- 2018 Co-Organizer, Fourth South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2018, Bariloche, Argentina
- 2018 Co-organizer, Symposium on G Proteins and GPCRs in Cancer, ASPET/EB Annual Meeting, San Diego, CA
- 2018 Organizer, Moores Cancer Center Science Retreat, La Jolla, CA
- 2019 Elected Co-Chair, Gordon Conference in Molecular Pharmacology, Ventura CA
- 2019 Organizer, Moores Cancer Center Science Retreat, La Jolla, CA

## **Funding and Support**

### Current Research Support

**R01DE026644** (MPI Gutkind/Lippman) 01/01/2017-12/31/2021

NIH/NIDCR

Targeting Signaling Vulnerabilities for Oral Cancer Prevention

The major goals of this project are to discover novel genomic markers of response and resistance to metformin in oral premalignancy, to test the influence of bioenergetic pathways involving

LKB1/AMPK, and mTOR and YAP inhibition in the activity of metformin, and to apply genetic screens to identify novel molecular mechanisms determining response or resistance to metformin.  
Role: MPI

**R01DE026870** (PI Gutkind) 08/01/2018-07/31/2023  
NIH/NIDCR

Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision Therapy

The goals of this project are to identify novel systems vulnerabilities cetuximab and PI3K/mTORi sensitization and the impact of targeting this pathway on the tumor and immune microenvironment.

Role: PI

**R01CA247551** (Gutkind/Cohen) 12/01/2019-11/30/2024  
NIH/NCI

Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC

The goals of this project are to elucidate the contribution of genomic alterations in the PI3K-mTOR signaling network to anti-HER3 sensitivity and resistance, and to establish the impact of targeting and co-targeting the HER3-PI3K/mTOR signaling network on the tumor immune microenvironment and response to PD-1 blockade, aiming at achieving a single cell level understanding of the anti-cancer immune response. These studies will inform the molecular stratification for patient selection in future multimodal precision immune oncology trials.

Role: MPI

**R33CA225291** (PI Gutkind) 06/05/2018-08/31/2020  
NIH/NCI

Area C: Genome-wide identification and targeting of resistance to cancer therapy.

This project aims to establish a new genome wide approach for identifying and targeting resistance pathways in cancer and experimentally test and study its applications in specific cancer types, including breast cancer, colon cancer, head and neck and melanoma.

Role: PI

**U01DE028227** (Schoenberger/Gutkind/Rao) 09/01/2018-08/31/2023  
NIH/NCI-NIDCR Cancer Moonshot Program

Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck Cancers.

The goals of this project is to study experimentally the tumor-T cell ecosystem in head and neck squamous cell carcinoma (HNSCC), and will exploit the emerging information to develop novel approaches to enhance the anti-tumor immune response, resulting in tumor regression (cure).

Role: MPI

**R25CA221779** (Gutkind/Sadler) 09/01/2019-08/31/2024  
NIH/NCI

Multidisciplinary Educational Approach to Reducing Cancer Disparities

San Diego's three NCI-designated Cancer Centers are collaborating in this Youth Enjoy Science Research Education (YES) Program. The Program is an intensive, long term, laboratory and community-based learning opportunity for UCSD students who are from communities that are underrepresented in cancer-related health and science careers. To gain mastery of their knowledge and skills in cancer disparities research, the student participants will be matched with a faculty mentor who will give them hands-on experiences in cancer-related research. Students

will also engage in a community-based cancer education campaign about cancer control, cancer disparities, and clinical trials.

Role: MPI

**R01CA221289** (PI Tesmer)

04/01/18 - 03/31/2023

NIH/NCI

Experimental study of the structural determinants of the activation of G protein-linked RhoGEFs in cells in vivo, and the contribution of G protein-regulated RhoGEFs in cancer in terms of signaling circuitries alterations, tumorigenic activity, and metastatic potential.

Role: Co-Investigator

**U54CA209891** (MPI Krogan/Ideker)

05/11/2017-4/30/2022

NIH/NCI

The Cancer Cell Map Initiative, a National Research Center for Cancer Systems Biology

The aim of the Cancer Cell Map Initiative is to apply systematic approaches to comprehensively map the molecular networks that underlie cancer and to use these maps as a key resource for precision medicine.

Role: Co-Investigator

#### Recently Completed Grant Support:

*The laboratory was funded from 1996-2015 by the NIDCR Intramural Research Program, NIH.*

- Project Z01DE00551, Molecular Mechanisms of Growth Control and Carcinogenesis
- Project Z01DE00558, Oral Carcinogenesis

2016 PEDAL15 Research Grant Award, Pedal the Cause. The GNAS-PKA Onco-Signaling Network in Colorectal Malignancies

2015 Million Dollar Bike Ride Pilot Grant, University of Pennsylvania Orphan Disease Center. Development of next-gen animal models for fibrous dysplasia (FD)/McCune-Albright syndrome (MAS)

2004-2015 Intramural AIDS Targeted Antiviral Program (IATAP)

Study of AIDS-associated malignancies, with emphasis on Kaposi's Sarcoma and HPV+ cancers

American Asthma Foundation (GPCR-trafficking and tachyphylaxis)

Human Science Frontier Program (Clonogenic cooperation in cancer)

#### **Clinical Protocols**

- NCT02581137, Metformin for Oral Cancer Prevention (M4OC-Prevent). UCSD Moores Cancer Center.  
PI: Scott Lippman; Gutkind J.S., Co-Lead. Completed, 2019.
- NCT01195922, A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer. NIDCR/NCI/NIDCD/MUSC.  
PI: Gutkind J.S. 2011. Completed, 2018.
- 14CN018. Pilot Study to Evaluate the Natural History of Head and Neck Cancer Precursors in Taiwan. NCI/NIDCR, 2014.  
PI: Anil Chaturvedi. Open.
- T-D-0024, The Molecular Anatomy of Oral Wound Healing. NIDCR.  
PI: Gutkind J.S. 2010. Completed, 2014.

## **Invention Reports and Patents:**

- U.S. Patent 5,384,243, issued January 24, 1995. J. Silvio Gutkind and Keith C. Robbins: Method for screening an agent for its ability to prevent cell transformation.
- NIH Ref No. E-302-2008, Chemoprevention of Head And Neck Squamous Cell Carcinomas. US Patent Application No. 13/059,335 filed August 20, 2009. Canadian Patent Application No. 2734828 filed August 20, 2009. European Patent Application No. 09791732.2 filed August 20, 2009
- NIH Ref No. E-282-2009, Sustained Release Delivery Systems for the Prevention and Treatment of Head and Neck Cancers. International Patent Application No. PCT/IL2010/000694 filed August 25, 2010
- U.S. Patent 9,151,762, issued October 6, 2015. J. Silvio Gutkind, Vyomesh Patel, Alfredo Molinolo, Timothy D. Veenstra. Identification of DSG3 as a Biomarker for the Detection of Metastasis in Lymph Nodes.
- U.S. Patent 9,278,090, issued March 8, 2016. J. Silvio Gutkind, Ramiro Iglesias-Bartolome, Vyomesh Patel, Ana p. Cotrim, Alfredo Molinolo, and James B. Mitchell. Methods of preventing the development of mucositis and related disorders.
- U.S. Application serial No. 62/832,425, filed on April 11, 2019. J. Silvio Gutkind, David Schlaepfer. New Anticancer Treatment for Uveal Melanoma.
- US San Diego Office of Innovation and Commercialization, Case No. SD2020-164, filed on October 21, 2020. J. Silvio Gutkind, Zhiyong Wang. New Multimodality Precision Immunotherapy for Head and Neck Cancer.
- U.S. Application serial No. 62/929,061, filed on October 31, 2019. J. Silvio Gutkind, Zhiyong Wang. Novel Syngeneic Animal Model of Tobacco-Associated Oral Cancer Reveals the Activity of in Sity Anti-CTLA-4.

## **Ph.D. Thesis Directed:**

G.M. Kalinec, Ph.D., University of Cordoba, Cordoba, Argentina, 1992  
M. Chiariello, M.D. Ph.D., University of Naples, Naples, Italy, 1999. Co-director  
L.M. Laguige, Ph.D., Catholic University of Cordoba, Cordoba, Argentina, 2000  
C. Leethanakul, D.D.S., Ph.D., Chulalongkorn University, Bangkok, Thailand, 2000  
P. Amornphimoltham, D.D.S., Ph.D., University of Maryland, 2006  
M.D. Castellone, M.D., Ph.D., University of Naples, Naples, Italy, 2005. Co-director  
K. Leelahavanichkul, D.D.S. Ph.D., Tammasat University, Bangkok, Thailand, 2011  
X. Feng, PhD., West China School of Stomatology, Sichuan University, Chengdu, China, 2013  
Ann Hoeben, M.D., Ph.D., Catholic University of Leuven, Belgium, 2014  
Z. Wang, Ph.D., West China School of Stomatology, Sichuan University, Chengdu, China, 2014  
X. Wu, Ph.D., West China School of Stomatology, Sichuan University, Chengdu, China, 2017  
X. Zhao, D.D.S., Ph.D., West China School of Stomatology, Sichuan University, Chengdu, China, 2018  
X. Zhang, D.D.S., Ph.D, West China School of Stomatology, Sichuan University, Chengdu, China, 2019

**Bibliography** [Author=(Gutkind J\* OR Gutkind S\*)]. [Pubmed](#)  
**Total 512 publications: 431 peer-reviewed studies, 47 review articles, 34 book chapters, with 58,103 citations and an H index of 107 [ISI] and 124 [Google Scholar]**

**Selected publications, signal transduction research:**

1. Crespo P., Xu N., Simonds W.F., and Gutkind J.S. Ras-dependent activation of MAP kinase pathway mediated by G-protein  $\beta\gamma$  subunits. *Nature*, **369**:418-420, 1994.
2. Coso O., Chiariello M., Yu J.-C., Crespo P., Teramoto, H., Xu N., Miki T., and Gutkind J.S. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK (SAPK) signaling pathway. *Cell*, **81**:1137-1148, 1995.
3. Lopez-Illasaca M., Crespo P., Pellici P.G., Gutkind J.S., and Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase  $\gamma$ . *Science*, **275**:394-397, 1997.
4. Crespo P., Schuebel K.E., Ostrom A.A., Gutkind J.S., and Bustelo X.R. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the *vav* proto-oncogene product. *Nature*, **385**:169-172, 1997.
5. Chiariello M., Marinissen M.J., and Gutkind J.S. Regulation of *c-myc* expression by PDGF through Rho GTPases. *Nature Cell Biol.*, **3**:580-586, 2001.
6. Montaner S., Sodhi A., Molinolo A., Bugge T.H., Sawai E.T., He Y., Li Y., Ray P.E., and Gutkind J.S. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. *Cancer Cell*, **3**:23-36, 2003.
7. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., and Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a novel Gs-axin- $\beta$ -catenin signaling axis. *Science*, **310**:1504-1510, 2005.
8. Martin D., Galisteo R., Molinolo A.A., Wetzker R., Hirsch E., and Gutkind J.S. PI3Ky mediates Kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. *Cancer Cell*, **19**: 805-813, 2011.
9. Yagi H., Tan W., Dillenburg-Pilla P., Armando S., Amornphimoltham P., Simaan M., Weigert R., Molinolo A.A., Bouvier M., and Gutkind J.S. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. *Science Signaling*, **4**: ra60, 2011.
10. Vaqué J.P., Dorsam R.T., Feng X., Iglesias-Bartolome R., Forsthoefel D.J., Chen Q., Debant A., Seeger M.A., Ksander B.R., Teramoto H., Gutkind J.S. A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing GPCR-initiated mitogenic signals. *Molecular Cell*, **49**:94-108, 2013.
11. O'Hayre M., Vázquez-Prado J., Kufareva I., Stawiski E.W., Handel T., Seshagiri S., and Gutkind J.S. The emerging mutational landscape of G-proteins and G-protein-coupled receptors in cancer. (Analysis) *Nature Reviews Cancer* **13**(6):412-424, 2013.
12. Feng K., Degese M.S., Iglesias-Bartolome R., Vaque J.P., Molinolo A.A., Rodrigues M., Zaidi M.R., Ksander B.R., Merlino M., Sodhi A., Chen Q., and Gutkind J.S. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a Trio-regulated Rho GTPase signaling circuitry. *Cancer Cell*, **25**:831-845, 2014.
13. Mikelis C.M., Simaan M., Ando K., Fukuhara S., Sakurai A., Amornphimoltham P., Masedunskas A., Weigert R., Chavakis T., Adams R., Offermanns S., Mochizuki N., Zheng Y., and Gutkind J.S. RhoA and ROCK mediate histamine-induced vascular leakage and anaphylactic shock. *Nature Commun.*, **6**:6725, 2015.
14. Iglesias-Bartolome R., Torres D., Marone R., Feng X., Martin D., Simaan M., Chen M., Weinstein L.S., Taylor S.S., Molinolo A.A., and Gutkind J.S., Inactivation of a Gas-PKA tumor suppressor pathway in skin stem cells initiates basal-cell carcinogenesis. *Nature*

- Cell Biol.*, **17**:793-803, 2015.
15. O'Hayre M., Eichel K., Avino S., Zhao X., Steffen D.J., Feng X., Kawakami K., Aoki J., Messer K., Sunahara R., Inoue A., von Zastrow M., and Gutkind J.S. Genetic evidence that  $\beta$ -arrestins are dispensable for the initiation of  $\beta$ 2-adrenergic receptor signaling to ERK. *Science Signaling*. **10(484)** pii: eaal3395, 2017.
  16. Zhao X., Deng P., Iglesias-Bartolome R., Amornphimoltham P., Steffen D.J., Jin Y., Molinolo A.A., de Castro L.F., Ovejero D., Yuan Q., Chen Q., Han X., Bai D., Taylor S.S., Yang Y., Collins M.T., and Gutkind J.S. Expression of an active Gas mutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance. *Proc Natl Acad Sci U.S.A.* **115**: E428-E437, 2017.
  17. Martin D., Degese M.S., Vitale-Cross L., Iglesias-Bartolome R., Callejas Valera J.L., Wang Z. Feng X., Yeerna H., Vadmal V., Moroishi T., Thorne R., Zaida M., Siegele B., Cheong S.C., Molinolo A.A., Samuels Y., Tamayo P., Guan K.L., Lippman SM., Lyons J.G., Gutkind J.S. Assembly and Activation of the Hippo Signalome by the FAT1 Tumor Suppressor. *Nature Comm.*, **9**:2372, 2018.
  18. Gutkind J.S., Kostenis E. Arrestins as rheostats of GPCR signaling. *Nat. Rev. Mol. Cell Biol.*, 2018 Jul 19. 10.1038/s41580-018-0041-y
  19. Wu V., Yeerna H., Nohata N., Chiou J., Harismendy O., Raimondi F., Inoue A., Russell R.B., Tamayo P., Gutkind J.S. Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. *J Biol Chem.* **294(29)**:11062-11086. 2019.
  20. Feng X, Arang N, Rigracciolo DC, Lee JS, Yeerna H, Wang Z, Lubrano S, Kishore A, Pachter JA, König GM, Maggiolini M, Kostenis E, Schlaepfer DD, Tamayo P, Chen Q, Ruppin E, Gutkind JS. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. *Cancer Cell.* **35(3)**:457-472.e5, 2019.

#### **Selected publications, oral cancer research:**

1. Amornphimoltham P., Patel V., Sodhi A., Nikitakis N.G., Sauk J.J., Sausville E.A., Molinolo A.A., and Gutkind J.S. mTOR, a molecular target in squamous cell carcinomas of the head and neck. *Cancer Research*, **65**:9953-9961, 2005.
2. Molinolo A.A., Hewitt S., Amornphimoltham P., Keelawat S., Rangdaeng S., Meneses García A., Raimondi A.R., Jufe R., Itoiz M., Gao Y., Saranath D., Kaleebi G.S., Yoo G.H., Leak L., Myers E.M., Shintani S., Wong D., Massey H.D., Yeudall W.A., Lonardo F., Ensley J., and Gutkind J.S. Dissecting the Akt/mTOR signaling network: Emerging results from the Head and Neck Cancer Tissue Array Initiative. *Clinical Cancer Research*, **13**:4964-4973, 2007.
3. Amornphimoltham P., Patel V., Leelahavanichkul K., Abraham R.T., and Gutkind J.S. A retro-inhibition approach reveals a tumor cell-autonomous therapeutic response to rapamycin in head and neck squamous cell carcinomas. *Cancer Research*, **68**:1144-1153, 2008.
4. Czerninski R., Amornphimoltham P., Patel V., Molinolo A.A., and Gutkind J.S. Targeting mTOR by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. *Cancer Prevention Research*, **2**:27-36, 2009.
5. Castilho R.M, Squarize C.H., Chodosh L.A., Williams B.O., and Gutkind J.S. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. *Cell Stem Cell*, **5**:279-289, 2009.
6. Patel V., Marsh C.A., Dorsam R.T., Masedunskas A., Amornphimoltham P., Nathan C.O., Singh B., Weigert R., Molinolo A.A., and Gutkind J.S. Decreased lymphangiogenesis and

- lymph node metastasis by mTOR inhibition in head and neck cancer. *Cancer Research*, **71**:7103-7112, 2011.
7. Molinolo A.A., Marsh C., El Dinali M., Gangane N., Jennison K., Hewitt S., Patel V., Seiwert T.Y., and Gutkind J.S.. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. *Clinical Cancer Research*, **18**:2558-2568, 2012.
  8. Vitale-Cross L., Molinolo A.A., Martin D., Younis R.H., Maruyama T., Patel P., Chen W., Schneider A., and Gutkind J.S.. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. *Cancer Prevention Research*, **5**:562-573, 2012.
  9. Iglesias-Bartolome R., Patel V., Cotrim A., Leelahavanichkul K., Molinolo A.A., Mitchell J.B., and Gutkind J.S. mTOR inhibition protects from epithelial stem cell senescence and radiation-induced mucositis. *Cell Stem Cell*, **11**:401-414, 2012.
  10. Iglesias-Bartolome R., Martin D., and Gutkind J.S. Exploiting the head and neck cancer oncogenome: Widespread PI3K-mTOR pathway alterations and novel molecular targets. *Cancer Discovery*, **3**:722-725, 2013.
  11. Wang Z., Martin D., Molinolo A.A., Patel V., Iglesias-Bartolome R., Degese M.S., Vitale-Cross L., Chen Q., and Gutkind J.S. mTOR inhibition overcomes cetuximab resistance in head and neck cancers harboring *PIK3CA* and *RAS* mutations. *J. Natl. Cancer Inst.*, **106**(9) 1-11, 2014.
  12. Madera1 D., Vitale-Cross L., Martin D., Schneider A., Molinolo A.A., Gangane N., Carey T.E., McHugh J.B., Komarck C.M., Walline H.M., William Jr. W.N., Seethala R.R., Ferris R., and Gutkind J.S. Prevention of tumor growth driven by *PIK3CA* and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. *Cancer Prevention Res. (AACR)*, **8**:197-207, 2015.
  13. Doçi C.L., Mikelis C.M., Lionakis M.S., Molinolo A.A., and Gutkind J.S. Genetic identification of SEMA3F as an anti-lymphangiogenic metastasis suppressor gene in head and neck squamous carcinoma. *Cancer Research*, **75**: 2937-2948, 2015.
  14. William W.N. Jr, Papadimitrakopoulou V., Lee J.J., Mao L., Cohen E.E., Lin H.Y., Gillenwater A.M., Martin J.W., Lingen M.W., Boyle J.O., Shin D.M., Vigneswaran N., Shinn N., Heymach J.V., Wistuba I.I., Tang X., Kim E.S., Saintigny P., Blair E.A., Meiller T., Gutkind J.S., Myers J., El-Naggar A., and Lippman S.M. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. *JAMA Oncol.*, **2**:209-216, 2016.
  15. Carter H., Marty R., Hofree M., Gross A., Jensen J., Fisch K.M., Wu X., DeBoever C., Van Nostrand E.L., Song Y., Wheeler E., Kreisberg J.F., Lippman S.M., Yeo G., Gutkind J.S., Ideker T. Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. *Cancer Discovery*. **7**:410-423, 2017
  16. Gutkind J.S and Bui J.D. The Next Frontier: Head and Neck Cancer Immunoprevention. *Cancer Prev. Res.* **10**:681-683, 2017.
  17. Iglesias-Bartolome R., Uchiyama A., Molinolo A.A., Abusleme L., Brooks S.R., Callejas-Valera J.L., Edwards D., Doci C., Asselin-Labat M.-L., Onaitis M.W., Moutsopoulos N.M., Gutkind\* J.S., Morraso\* M.I. (\*Co-corresponding authors). Transcriptional signature primes human oral mucosa for rapid wound healing. *Sci. Transl. Med.*, 2018, **10**, eaap8798
  18. Wang Z., Feng X., Molinolo A.A., Martin D., Vitale-Cross L., Nohata N., Ando M., Wahba A., Amornphimoltham P., Wu X., Gilardi M., Allevalo M., Wu V., Steffen D.J., Tofilon P., Sonenberg N., Califano J., Chen Q., Lippman S.M., Gutkind J.S. 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer. *Cancer Res.* 2019.
  19. Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin K, Sood AJ, Kompelli A, Vick JA, Martin D, Vitale-Cross L, Callejas-Varela JL, Wang Z, Wu X, Harismendy O, Molinolo AA,

- Lippman SM, Van Waes C, Szabo E, Gutkind JS. Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. *Clin Cancer Res.* **25**(4):1156-1164, 2019.
20. Wang Z., Wu V.H., Allevato M.M., Gilardi M., He Y., Callejas-Valera J.L., Vitale-Cross L., Martin D., Amornphimoltham P., Mcdermott J., Yung B.S., Goto Y., Molinolo A.A., Sharabi A.B., Cohen E.E.W. Chen Q., Lyons J.G., Alexandrov L.B., Gutkind J.S. Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. *Nature Comm.*, **10**(1):5546, 2019.

## Complete Bibliography

### Peer Reviewed Research Articles

1. Gutkind J.S. and Enero M.A. Noradrenaline uptake inhibitors counteract the cardiovascular effects of clonidine but not those of guanabenz. *Commun. Biol.*, **1**:319-326, 1983.
2. Gutkind J.S. and Enero M.A. Treatment with clorgyline and pargyline differentially decreases clonidine-induced hypotension and bradycardia. *Naunyn Schmiedeberg's Arch. Pharmacol.*, **327**:189-192, 1984.
3. Gutkind J.S., Bogнар I., and Enero M.A. Pharmacological characterization of guanabenz, clonidine-like anti-hypertensive drug. *J. Cardiol. (Argentina)*, **53**:145-147, 1985.
4. Gutkind J.S., Kazanietz M.G., and Enero M.A. Cardiovascular effects of alpha-adrenergic drugs: differences between clonidine and guanabenz. *Naunyn Schmiedeberg's Arch. Pharmacol.*, **332**:370-375, 1986.
5. Gutkind J.S. and Enero M.A. Effects of desipramine on the cardiovascular responses to clonidine and guanabenz. *Hypertension*, **8**:184-186, 1986.
6. Kazanietz M.G., Gutkind J.S., and Enero M.A. Interaction between  $\alpha_2$ - and  $\beta_2$ -adrenoceptor responses in the vascular system: effect of clenbuterol. *Eur. J. Pharmacol.*, **130**:119-124, 1987.
7. Castren E., Kurihara M., Gutkind J.S., and Saavedra J.M. Specific angiotensin II binding sites in the rat stellate and superior cervical ganglion. *Brain Research*, **422**:347-351, 1987.
8. Gutkind J.S. and Enero M.A. Different pharmacological interaction of clonidine and guanabenz with antidepressive drugs. *Clin. Exper. Hypertension*, **A9**:1531-1547, 1987.
9. Gutkind J.S., Kurihara M., Castren E., and Saavedra J.M. Atrial natriuretic peptide receptors in sympathetic ganglia: Biochemical response and alterations in genetically hypertensive rats. *Biochem. Biophys. Res. Commun.*, **149**:65-72, 1987.
10. Kurihara M., Castren E., Gutkind J.S., and Saavedra J.M. Lower number of atrial natriuretic peptide receptors in thymocytes and spleen cells of spontaneously hypertensive rats. *Biochem. Biophys. Res. Commun.*, **149**:1132-1140, 1987.
11. Saito K., Gutkind J.S., and Saavedra J.M. Angiotensin II binding sites in the conduction system of the rat heart. *Am. J. Physiol.*, **253**: (Heart Circ. Physiol. 22), H1618-H1622, 1987.
12. Gutkind J.S., Kurihara M., Castren E., and Saavedra J.M. Increased concentration of angiotensin II binding sites in selected brain areas of spontaneously hypertensive rats. *J. Hypertension*, **6**:79-84, 1988.
13. Kurihara M., Gutkind J.S., Saavedra J.M. Alteration of atrial natriuretic peptide binding sites in spontaneously hypertensive rats. *Am. J. Hypertension*, **1**:12S-14S, 1988.
14. Kurihara M., Castren E., Gutkind J.S., Saito K., and Saavedra J.M. Characterization of  $\beta$ -adrenergic receptors in sections from human blood lymphocyte pellets by quantitative auto-radiography. *Biological Psychiatry*, **23**:746-749, 1988.

15. Nazarali A.J., Gutkind J.S., and Saavedra J.M. Regulation of angiotensin II binding sites in discrete rat brain nuclei after water deprivation. *Cell. Molec. Neurobiol.*, **7**:447-455, 1988.
16. Gutkind J.S., Castren E., and Saavedra J.M. Decreased angiotensin II binding in the anterior pituitary gland of spontaneously hypertensive rats. *Life Science*, **43**:441-451, 1988.
17. Gutkind J.S., Kurihara M., Castren E., and Saavedra J.M. Autoradiographic quantification of vasoactive intestinal peptide binding sites in sections from human blood lymphocytes pellets. *Neuropsychopharmacol.*, **1**:251-255, 1988.
18. Gutkind J.S., Kurihara M., and Saavedra J.M. Increased angiotensin II receptors in brain nuclei of DOCA-salt hypertensive rats. *Am. J. Physiol.*, **255**: (Heart Circ. Physiol. 24), H646-H650, 1988.
19. Nazarali A.J., Gutkind J.S., Correa F.M.A., and Saavedra J.M. Effect of chronic administration of the converting enzyme inhibitor enalapril (MK 421) on brain atrial natriuretic peptide receptors in Wistar-Kyoto and spontaneously hypertensive rats. *Brain Research*, **475**:134-140, 1988.
20. Gutkind J.S., Kazanietz M.G., Armando I., Puyo A., and Enero M.A. Pressor response induced by clenbuterol treatment in immobilized normotensive rats. *J. Cardiovasc. Pharmacol.*, **13**:793-798, 1989.
21. Kazanietz M.G., Gutkind J.S., Puyo A., Armando I., and Enero, M.A. Further evidence for interaction between vasodilators beta-2-adrenoceptor and vasoconstriction-alpha-2-adrenoceptor mediated responses in maintaining vascular tone in anesthetized rats. *J. Cardio. Pharmacol.*, **14**:874-880, 1989.
22. Nazarali A.J., Gutkind J.S., Correa F.M.A., and Saavedra J.M. Selective decrease of angiotensin II receptors in the subfornical organ of spontaneously hypertensive rats after chronic treatment with a converting enzyme inhibitor. *Am. J. Physiol.*, **256**:H1609-H1614, 1989.
23. Nazarali A.J., Gutkind J.S., and Saavedra J.M. Calibration of [<sup>125</sup>I]-polymer standards with [<sup>125</sup>I]-brain paste standards for use in quantitative receptor autoradiography. *J. Neurosc. Methods*, **30**:247-253, 1989.
24. Sugita K., Gutkind J.S., Katamine S., and Robbins K.C. The actin domain of Gardner-Rasheed feline sarcoma virus inhibits kinase and transforming activities. *J. Virology*, **63**:1715-1720, 1989.
25. Notario V., Gutkind J.S., Imaizumi M., Katamine S., and Robbins K.C. Expression of the *fgr* proto-oncogene product as a function of myelomonocytic cell maturation. *J. Cell Biol.*, **109**:3129-3136, 1989.
26. Gutkind J.S. and Robbins K.C.: Mobilization of the *c-fgr* protein-tyrosine kinase as a consequence of neutrophil activation. *Proc. Natl. Acad. of Sci. USA*, **86**:8783-8787, 1989.
27. Gutkind J.S., Lacal P.M., and Robbins K.C. Thrombin-dependent association of phosphatidylinositol-3 kinase with p60<sup>c-src</sup> and p59<sup>fyn</sup> in human platelets, *Mol. Cell. Biol.*, **10**:3806-3809, 1990.
28. Benhamou M., Gutkind J.S., Robbins K.C., and Siraganian R.P. Tyrosine phosphorylation coupled to IgE receptor-mediated signal transduction and histamine release. *Proc. Natl. Acad. Sci. USA*, **87**:5327-5330, 1990.
29. Vukicevic S., Paralkar V.M., Cunningham N.S., Gutkind J.S., and Reddi A.H. Autoradiographic localization of osteogenin binding sites in cartilage and bone during rat embryonic development. *Dev. Biol.*, **140**:209-214, 1990.
30. Heidarani M.A., Pierce J.H., Lombardi D., Ruggiero M., Gutkind J.S., Matsui T., and Aaronson S.A. Deletion or substitution within the  $\alpha$  PDGF receptor kinase insert domain: effects on functional coupling with intracellular signaling pathways. *Mol. Cell. Biol.*, **11**:134-142, 1991.

31. Yu, J.-C., Heidarman M.A., Pierce J.H., Gutkind J.S., Lombardi D., Ruggiero M., and Aaronson S.A. Tyrosine mutations within the  $\alpha$ PDGF kinase insert domain abrogate receptor-associated PI-3 kinase activity without affecting mitogenic or chemotactic signal transduction. *Mol. Cell. Biol.*, **11**:3780-3785, 1991.
32. Gutkind J.S., Link D.C., Katamine S., Lacal P., Miki T., Ley T.J., and Robbins K.C. A novel *c-fgr* exon utilized in Epstein-Barr virus infected B-lymphocytes but not normal monocytes. *Mol. Cell. Biol.*, **11**:1505-1507, 1991.
33. Gusovsky F. and Gutkind J.S.: Selective effect of activation of protein kinase-C isoenzymes on cAMP accumulation. *Mol. Pharmacol.*, **39**:124-129, 1991.
34. Gutkind J.S., Novotny E., Brann M.R., and Robbins K.C. Muscarinic acetylcholine receptor subtypes as agonist dependent oncogenes. *Proc. Natl. Acad. Sci. USA*, **88**:4703-4707, 1991.
35. Hermouet S., Merendino J. Jr., Gutkind J.S., and Spiegel A.M. Activating and inactivating mutations of  $G_{\alpha_{i2}}$  have opposite effects on proliferation of NIH 3T3 cells. *Proc. Natl. Acad. Sci. USA*, **88**:10455-10459, 1991.
36. Sartor O., Moriuchi R., Sameshima J., Severino M., Gutkind J.S., and Robbins K.C. Diverse biologic properties imparted by the *c-fgr* proto-oncogene. *J. Biol. Chem.*, **267**:3460-3465, 1992.
37. Volker S., Benhamou M., Gutkind J.S., Robbins K.C., and Siraganian R.P. Fc $\epsilon$ R1-induced protein tyrosine phosphorylation of pp72 in rat basophilic leukemia cells (RBL-2H3): Evidence for a novel signal transduction pathway unrelated to G protein activation and phosphatidylinositol hydrolysis. *J. Biol. Chem.*, **267**:5434-5441, 1992.
38. Thompson P.A., Gutkind J.S., Robbins K.C., Ledbetter J.A., and Bolen J.B. Identification of distinct populations of PI-3 kinase following T cell activation. *Oncogene*, **7**:719-725, 1992.
39. Link D.C., Gutkind J.S., Robbins K.C., and Ley T.J. Characterization of the 5' untranslated region of the human *c-fgr* gene and identification of the major myelomonocytic *c-fgr* promoter. *Oncogene*, **7**:877-884, 1992.
40. Kalinec G., Nazarali A.J., Hermouet S., Xu N., and Gutkind J.S. Mutated  $\alpha$  subunit of the  $G_q$  protein induces malignant transformation in NIH 3T3 cells. *Mol. Cell. Biol.*, **12**:4687-4693, 1992.
41. Gutkind J.S. and Robbins K.C. Activation of transforming G protein-coupled receptors induces rapid tyrosine phosphorylation of cellular proteins, including p125<sup>FAK</sup> and the p130 v-src substrate. *Biochem. Biophys. Res. Commun.*, **188**:155-161, 1992.
42. Wang L.-M., Keegan A.D., Paul W.E., Heidarman M.A., Gutkind J.S., and Pierce J.H. IL-4 activates a distinct signal transduction cascade from IL-3 in factor dependent myeloid cells. *EMBO J.*, **11**:4899-1908, 1992.
43. Stephens E.V., Kalinec G., Brann M.R., and Gutkind J.S. Transforming G protein-coupled receptors transduce potent mitogenic signals in NIH 3T3 cells independent of cAMP-inhibition or conventional protein kinase C. *Oncogene*, **8**:19-26, 1993.
44. Wang L.-M., Keegan A.D., Li W., Lienhard G.E., Pacini S., Gutkind J.S., Myers M.G., Sun X.-J., White M.F., Aaronson S.A., Paul W.E., and Pierce J.H. Common elements in IL-4 and insulin signaling pathways in factor dependent hematopoietic cells. *Proc. Natl. Acad. Sci. USA* **90**:4032-4036, 1993.
45. Xu N., Bradley L., Ambdukar I., and Gutkind J.S. A mutant  $\alpha$  subunit of  $G_{12}$  potentiates the eicosanoid pathway and is highly oncogenic in NIH 3T3 cells. *Proc. Natl. Acad. Sci. USA*, **90**:6741-6745, 1993.
46. Xu N., McCormick F., and Gutkind J.S. The non-catalytic domain of *ras*-GAP inhibits transformation induced by G protein coupled receptors. *Oncogene*, **9**:597-602, 1994.

47. Xu N., Voyno-Yasenetskaya T., and Gutkind J.S. Potent transforming activity of the G<sub>13α</sub> subunit defines a novel family of oncogenes. *Biochem. Biophys. Res. Commun.*, **201**:603-609, 1994.
48. Calderon S.N., Izenwasser S., Heller B., Gutkind J.S., Mattson M., Su T.-P., and Newman A.H. Novel 1-phenylcycloalkanecarboxylic acid derivatives are potent and selective sigma<sub>1</sub> ligands. *J. Med. Chem.*, **37**:2285-2291, 1994.
49. Crespo P., Xu N., Daniotti J.L, Rapp U.R, and Gutkind J.S. Signaling through transforming G protein-coupled receptors in NIH 3T3 cells involves c-Raf activation: Evidence for a protein kinase C independent pathway. *J. Biol Chem.*, **269**:21103-21109, 1994.
50. Crespo P., Xu N., Simonds W.F., and Gutkind J.S. Ras-dependent activation of MAP kinase pathway mediated by G-protein βγ subunits. *Nature*, **369**:418-420, 1994.
51. Yu J.-C., Gutkind J.S., Mahadevan D., Li W., Meyers K.A., Pierce J.H., and Heidaran M.A. Biological function of PDGF-induced PI-3 kinase activity: Its role in αPDGF receptor-mediated mitogenic signaling. *J. Cell Biol.*, **127**:479-488, 1994.
52. Coso O., Chiariello M., Kalinec G., Kyriakis J., Woodgett J., and Gutkind J.S. Transforming G protein-coupled receptors potently activate JNK (SAPK): evidence for a divergence from the tyrosine-kinase signaling pathway. *J. Biol. Chem.*, **270**:5620-5624, 1995.
53. Crespo P., Cachero T.G., Xu N., and Gutkind J.S. Dual effect of β-adrenergic receptors on MAP kinase: Evidence for a βγ-dependent activation and a Gα<sub>s</sub>-cAMP-mediated inhibition. *J. Biol. Chem.*, **270**:25259-25265, 1995.
54. Crespo P., Mischak H., and Gutkind J.S. Overexpression of mammalian protein kinase C-ζ does not affect the growth characteristics of NIH 3T3 cells. *Biochem. Biophys. Res. Commun.*, **213**:266-272, 1995.
55. Mahadevan D., Thaki N., Singh J., McPhie P., Zangrilli D., Wang L.-M., Guerrero C., LeVine H., Humblet C., Saldanha J., Gutkind J.S., and Haske T. Structural studies on the PH domains of Dbl, Sos1, IRS-1 and βARK1 and their differential binding to Gβγ subunits. *Biochemistry J.* **34**:9111-9117, 1995.
56. Miyamoto S., Teramoto H., Coso O., Gutkind J.S., Burbelo P.D., Akiyama S.K., and Yamada K.M. Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. *J. Cell. Biol.*, **131**:791-805, 1995.
57. Coso O., Chiariello M., Yu J.-C., Crespo P., Teramoto, H., Xu N., Miki T., and Gutkind J.S. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK (SAPK) signaling pathway. *Cell*, **81**:1137-1148, 1995.
58. Coso O.A., Teramoto H., Simonds W.F., and Gutkind J.S. Signaling from G protein-coupled receptors to JNK/SPK involves βγ subunits of heterotrimeric G proteins acting on a Ras and Rac1-dependent pathway. *J. Biol. Chem.*, **271**:3963-3966, 1996.
59. Xu N., Coso O.A., Mahadevan D., De Blasi A., Goldsmith P.K., Simonds W.F., and Gutkind J.S. The PH domain of Ras-GAP is sufficient for in vitro binding to βγ subunits of heterotrimeric G proteins. *Cell. Mol. Neurobiol.*, **16**:51-59, 1996.
60. Cuvillier O., Pirianov G., Kleuser B., Vanek P.G., Coso O.A., Gutkind J.S., and Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. *Nature*, **381**:800- 803, 1996.
61. Zhang S., Coso O.A., Collins R., Gutkind J.S., and Simonds W.F. A carboxyl-terminal mutant of the G-protein β subunit deficient in the activation of phospholipase C-β. *J. Biol. Chem.*, **271**:20208-20211, 1996.
62. Kieser A., Adler H.S., Seitz T., Crespo P., Gutkind J.S., Kolch W., and Mischak H. Protein Kinase Cζ inhibits cellular transformation by upregulating *jun*-B and *egr*-1 expression. *Genes and Development*, **10**:1455-1466, 1996.

63. Crespo P., Bustelo X.R., Aaronson D.S., Coso O.A., Lopez-Barahona M., Barbacid M., and Gutkind J.S. Rac-1 dependent stimulation of the JNK/SAPK pathway by Vav. *Oncogene*, **13**:455-460, 1996.
64. Sundaresan M., Yu Z.-X., Ferrans V.J., Sulciner D.J., Gutkind J.S., Irani K., Goldschmidt-Clermont P.J., and Finkel T. Regulation of Reactive oxygen species generation in fibroblast by Rac1. *Biochem. J.*, **318**:379-382, 1996.
65. Calderon S.N., Bertha C.M., Gutkind J.S., Xu H., Partilla J.S., Rothman R.B., and Rice K. C. Probes for Narcotic receptor mediated phenomena. Synthesis and characterization of optically pure [<sup>3</sup>H](+)-4-[( $\alpha$ R)- $\beta$  -((2S,5R)-4-Propyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,Ndiethylbenzamide, [<sup>3</sup>H]SNC121, a novel high affinity and selective ligand for delta opioid receptors. *J. Labelled Comp. Radiopharm.* **38**:347-350, 1996.
66. Teramoto H., Crespo P., Coso O.A., Igishi T., Xu N., and Gutkind J.S. The small GTP-binding protein Rho activates JNK/SAPK in human kidney 293T cells: Evidence for a Pak-independent signaling pathway. *J. Biol. Chem.*, **271**:25731-25734, 1996.
67. Teramoto H., Coso O.A., Miyata H., Igishi T., and Gutkind J.S. Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the JNK/SAPK pathway: A role for MLK3/PTK1, a novel member of the mixed-lineage kinase family. *J. Biol. Chem.*, **271**:27225-27228, 1996.
68. Zhang S., Coso O.A., Lee C., Gutkind J.S., and Simonds W.F. Selective activation of effector pathways by brain-specific G protein  $\beta$ 5. *J. Biol. Chem.*, **271**:33575-33579, 1996.
69. Miyamoto S., Teramoto H., Gutkind J.S., and Yamada K.M. Integrins can synergize with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: Roles of integrin aggregation and occupancy of receptors. *J. Cell Biol.*, **135**:1633-1642, 1996.
70. Herrera L., Hinrichs M.V., Frías J., Gutkind J.S., and Olate J. Dual transduction signaling by a xenopus muscarinic receptor: Adenylyl cyclase inhibition and MAPK activation. *J. Cell. Biochem.*, **64**:1-8, 1997.
71. Lopez-Illasaca M., Crespo P., Pellici P.G., Gutkind J.S.\*, and Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase  $\square$ . *Science*, **275**:394-397, 1997.
72. Gordeladze J.O., Hovik K.E., Merendino J.J., Hermouet S., Gutkind J.S., and Accili D. Effect of activating and inactivating mutations of G<sub>s</sub>- and G<sub>i2</sub>-alpha protein subunits on growth and differentiation of 3T3-L1 preadipocytes. *J. Cell. Biochem.*, **64**:242-257, 1997.
73. Crespo P., Schuebel K.E., Ostrom A.A., Gutkind J.S., and Bustelo X.R. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. *Nature*, **385**:169-172, 1997.
74. Gutkind J.S., Crespo P., Xu N., Teramoto H., and Coso O.A. The pathway connecting m2 receptors to the nucleus involves small GTP-binding proteins acting on divergent MAP kinase cascades. *Life Sci.*, **60**:999-1006, 1997.
75. Teramoto H., Salem P., Robbins K.C., Bustelo X., and Gutkind J.S. Tyrosine phosphorylation of the vav proto-oncogene product links Fc $\epsilon$ RI to the Rac1-JNK pathway. *J. Biol. Chem.*, **272**:10751-10755, 1997.
76. Lopez-Illasaca M., Li W., Uren A., Yu J.-C., Kazlauskas A., Gutkind J.S., and Heidaran M.A. Requirement of phosphatidylinositol-3 kinase for activation of JNK/SAPKs by PDGF- $\beta$  receptors. *Biochem. Biophys. Res. Commun.*, **232**:273-277, 1997.
77. Buckbinder L., Velasco-Miguel S., Xu N., Chen Y., Talbott R., Gelbert L., Gao J., Seizinger B.R., Gutkind J.S., and Kley N. Inhibition of G protein-mediated activation of the MAP kinase pathway by a novel target of the p53 tumor suppressor. *Proc. Natl. Acad. Sci. U.S.A.*, **94**:7868-7872, 1997.
78. Coso O.A., Montaner S., Fromm C., Teramoto H., Prywes R., Lacal J.C. and Gutkind J.S. Signaling from G protein-coupled receptors to the c-jun promoter involves the MEF2

- transcription factor: evidence for a Novel JNK-independent pathway. *J. Biol. Chem.*, **272**:20691-20697, 1997.
79. Uren A., Jakus J., Font de Mora J., Yeudall A., Santos E., Gutkind J.S., and Heidaran M.A. Carboxy-terminal domain of p27Kip1 activates cdc2. *J. Biol. Chem.*, **272**:2669-2672, 1997.
  80. Fromm C., Coso O.A., Montaner S., Xu N., and Gutkind J.S. The small GTP-binding protein Rho links G protein-coupled receptors and G $\alpha_{12}$  to the serum response element and to cellular transformation. *Proc. Natl. Acad. Sci. U.S.A.*, **94**:10098-10103, 1997.
  81. Jin D.-Y., Teramoto H., Giam L.-Z., Chun R.F., Gutkind J.S., and Jeang K.-T. A human suppressor of JNK activation by TNF $\alpha$ . *J. Biol. Chem.*, **272**:25816-25823, 1997.
  82. Liu J.L., Blakesley V.A., Gutkind J.S., and Le Roith D. The constitutively active mutant of G $\alpha_{13}$  transforms mouse fibroblast cells deficient in insulin-growth factor-I receptor. *J. Biol. Chem.*, **272**:29438-29441, 1997.
  83. Bustelo X.R., Crespo P., Lopez-Barahona M., Gutkind J.S., and Barbacid M. Cbl-b, a member of the sli-1/c-cbl protein family inhibits Vav-mediated c-Jun N-terminal kinase activation. *Oncogene*, **15**:2511-2520, 1997.
  84. Alimandi M., Heidaran M.A., Gutkind J.S., Zhang J., Ellmore N., Kazalaukas V.M., Pierce J.H., and Li Q. PLC- $\gamma$  activation is required for PDGF- $\beta$ R-mediated mitogenesis and monocytic differentiation in myeloid progenitor cells. *Oncogene*, **15**:585-593, 1997.
  85. Bais C., Santomasso B., Coso O.A., Arvanitakis L., Raaka E., Gutkind J.S., Asch A., Cesarman E., Gershengorn M.C., and Mesri E. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor is a viral oncogene and angiogenesis activator. *Nature*, **391**:86-89, 1998.
  86. Lopez-Illasaca M., Gutkind J.S., and Wetzker R. Phosphoinositide 3-kinase  $\gamma$  is a mediator of G $\beta\gamma$ -dependent Jun kinase activation. *J. Biol. Chem.*, **273**:2505-2508, 1998.
  87. Jones T.L.Z. and Gutkind J.S. G $\alpha_{12}$  requires acylation for its transforming activity. *Biochemistry*, **37**:3196-3202, 1998.
  88. Igishi T. and Gutkind J.S. Tyrosine kinases of the Src family participate in signaling to MAP kinase from both Gq and Gi-coupled receptors. *Biochem. Biophys. Res. Commun.*, **244**:5-10, 1998.
  89. Rubino D., Driggers P., Arbit D., Kemp L., Miller B., Coso O., Pagliai K., Gray K., Gutkind J.S. and Segars J. Characterization of Brx, a novel DBL family member that modulates estrogen receptor action. *Oncogene*, **16**:2513-2526, 1998.
  90. Chiariello M., Visconti R., Carlomagno F., Melillo R.M., Bucci C., de Franciscis V., Fox G.M., Jing S., Coso O.A., Gutkind J.S., Fusco A., and Santoro M. Signaling of the Ret receptor tyrosine kinase through the JNK: evidence for a divergence of the ERKs and JNKs pathways induced by Ret. *Oncogene*, **16**:2435-2447, 1998.
  91. Zohar M., Teramoto H., Katz B.-Z., Yamada K.M., and Gutkind J.S. Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation. *Oncogene*, **17**:991-998, 1998.
  92. Murga C., Laguinde L., Wetzker R., Cuadrado A., and Gutkind J.S. Activation of Akt/PKB by G protein-coupled receptors: A role for  $\alpha$  and  $\beta\gamma$  subunits of heterotrimeric G proteins acting through PI3K $\gamma$ . *J. Biol. Chem.*, **273**:19080-19085, 1998.
  93. Deb T.B., Wong L., Salomon D.S., Zhou G.C., Dixon J.E., Gutkind J.S., Thompson S.A., and Johnson G.R. A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors - A specific role for SHP-2 in MAPK, but not c-jun amino-terminal kinase activation. *J. Biol. Chem.*, **273**:16643-16646, 1998.
  94. Crespo P., de Mora J.F., Aaronson D.S., Santos E., and Gutkind J.S.: Transforming G protein-coupled receptors block insulin and ras-induced adipocytic differentiation in 3T3-

- L1 cells: Evidence for a PKC and MAP kinase independent pathway. *Biochem. Biophys. Res. Commun.*, **245**:554-561, 1998.
95. Okubo Y., Blakesley V.A., Stannard B., Gutkind J.S., and Le Roith D. Insulin-like growth factor-I inhibits the stress-activated protein kinase/c-Jun N-terminal kinase. *J. Biol. Chem.*, **273**:25961-25966, 1998.
  96. Burstein E.S., Hesterberg D.J., Gutkind J.S., Brann M.R., Currier E.A., and Messier T.L. The ras-related GTPase rac1 regulates a proliferative pathway selectively utilized by G-protein coupled receptors. *Oncogene*, **17**:1617-1623, 1998.
  97. Patel V., Senderowicz A.M., Pinto D., Ensley J., Igishi T., Sausville E.A., and Gutkind J.S. Flavopiridol, a novel CDK inhibitor, suppresses the growth of squamous cell carcinomas by inducing apoptosis. *J. Clin. Invest.*, **102**:1674-1681, 1998.
  98. Korn I., Gutkind J.S., Srinivasan N., Blundell T.L., Allende C.C, and Allende J.E. Interactions of protein kinase CK2 subunits. *Mol. Cell. Biochem.*, **191**:75-83, 1999.
  99. Janulis M., Silberman S., Ambegaokar A., Gutkind J.S., and Schultz R.M. Role of mitogen-activated protein kinases and c-Jun/AP-1 trans-activating activity in the regulation of protease mRNAs and the malignant phenotype in NIH 3T3 fibroblasts. *J. Biol. Chem.*, **274**:801-813, 1999.
  100. Fukuhara S., Murga C., Zohar M., Igishi T., and Gutkind J.S. A novel PDZ-domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho. *J. Biol. Chem.*, **274**:5868-5879, 1999.
  101. Heemskerk F., Zorad S., Xu N., Gutkind J.S., and Saavedra J.M. Characterization of AT2 receptor expression in NIH 3T3 fibroblasts. *Cell. Mol. Neurobiol.*, **19**:277-288, 1999.
  102. Soon L., Flechner L., Gutkind J. S., Wang L.-H., Baserga R., Pierce J. H., and Li W. Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of IRS expression. *Mol. Cell. Biol.*, **19**:3816-3824, 1999.
  103. Pece S., Chiariello M., Murga C., and Gutkind J.S. Activation of the protein kinase Akt/PKB by the formation of E-cadherin-mediated cell-cell junctions - Evidence for the association of phosphatidylinositol 3-kinase with the E-cadherin adhesion complex. *J. Biol. Chem.*, **274**:19347-19351, 1999.
  104. Marinissen M.J., Chiariello M., Pallante M., and Gutkind J.S. A network of mitogen-activated protein kinases links G protein-coupled receptors to the *c-jun* promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5. *Mol. Cell. Biol.*, **19**:4289-4301, 1999.
  105. Scita G., Nordstrom J., Carbone R., Tenca P., Giardina G., Gutkind J.S., Bjarnegård M., Betsholtz C., Di Fiore P.P. EPS8 and E3B1 Transduce signals from Ras to Rac. *Nature* **40**:290-293, 1999.
  106. Igishi T., Fukuhara S., Patel V., Katz B.Z., Yamada K.M., and Gutkind J.S. Divergent signaling pathways link FAK to MAP kinase cascades: A role for paxillin in JNK activation. *J. Biol. Chem.*, **274**:30738-30746, 1999.
  107. Lerga A., Crespo P., Berciano M., Delgado M.D., Cañelles M., Calés C., Richard C., Ceballos E., Gutierrez P., Ajenjo N., Gutkind J.S., and Leon J. Regulation of c-Myc and Max in megakaryocytic and monocytic-macrophagic differentiation of K562 cells induced by protein kinase C modifiers: c-Myc is down-regulated but does not inhibit differentiation. *Cell Growth Diff.*, **10**:639-654, 1999.
  108. Tassi E., Biesova Z., Di Fiore P.P., Gutkind J.S., and Wong W.T. Human JIK, a novel member of the STE20 kinase family that inhibits JNK and is negatively regulated by EGF. *J. Biol. Chem.*, **274**:33287-33295, 1999.
  109. Chiang Y.J., Kole H.K., Brown K., Naramura M., Fukuhara S., Hu R.J., Jang I.K., Gutkind J.S., Shevach E., and Gu H. Cbl-b regulates the CD28 dependence of T-cell activation. *Nature*, **403**:216-220, 2000.

110. Shillitoe E.J., May M., Leethanakul C., Patel V., Ensley J.F., Strausberg R.L., and Gutkind J.S. Genome-wide analysis of oral cancer-Early results from the Cancer Genome Anatomy Project. *Oral Oncol.*, **36**:8-16, 2000.
111. Chiariello M., Marinissen M.J, and Gutkind J.S. Multiple MAP kinase signaling pathways connect the Cot oncoprotein to the *c-jun* promoter and to cellular transformation. *Mol. Cell. Biol.*, **20**:1747-1758, 2000.
112. Majidi M., Gutkind J.S., and Lichy J.H. Deletion of the COOH terminus converts the ST5 p70 Protein from an inhibitor of RAS signaling to an activator with transforming activity in NIH-3T3 Cells. *J. Biol. Chem.*, **275**:6560-6565, 2000.
113. Katz B.Z., Zohar M., Teramoto H., Matsumoto K., Gutkind J.S., Lin D.C., Lin S., and Yamada K.M. Tensin can induce JNK and p38 activation. *Biochem. Biophys. Res. Commun.*, **272**: 717-720, 2000.
114. Pirone D.M., Fukuhara S., Gutkind J.S., Burbelo P.D. SPECs, Small Binding Proteins for Cdc42. *J. Biol. Chem.*, **275**:22650-22656, 2000.
115. Sanchez-Prieto R., Rojas J.M., Taya Y., and Gutkind J.S. A role for the p38<sup>MAPK</sup> pathway in the transcriptional activation of p53 upon genotoxic stress by chemotherapeutic agents. *Cancer Res.*, **60**: 2464-2472, 2000.
116. Izevbigie E.B.O., Gutkind J.S., and Ray P. E. Angiotensin II and Fibroblast Growth Factor mitogenic signaling pathways in human mesangial cells. *Pediatr. Res.*, **47**: 614-621, 2000.
117. Murga C., Fukuhara S., and Gutkind J.S. A novel role for PI3-kinase  $\beta$  in signaling from G protein-coupled receptors to Akt. *J. Biol. Chem.*, **275**: 12069-12073, 2000.
118. Chiariello M., Gomez E., and Gutkind J.S. Regulation of the mammalian G1/S cell cycle restriction point by MAP kinase. *J. Biochem.*, **349**:869-876, 2000.
119. Leethanakul C., Patel V., Gillespie J., Shillitoe E., Kellman R.M., Ensley J.E., Limwongse V., Emmert-Buck M.R., Krizman D.V., and Gutkind J.S. Gene expression profiles in squamous cell Carcinomas of the oral cavity: Use of Laser Capture Microdissection for the construction and analysis of stage-specific cDNA libraries. *Oral Oncology*, **36**:474-483, 2000.
120. Leethanakul C., Patel V., Gillespie J., Pallante M., Ensley J.F., Liotta L.A., Emmert-Buck M., and Gutkind J.S. Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. *Oncogene*, **19**:3220-3224, 2000.
121. Izevbigie E.B.O., Gutkind J.S., and Ray P. Isoproterenol inhibits FGFb-induced growth of renal epithelial cells. *Ped. Nephrology*, **14**: 726-734, 2000.
122. Visconti R., Gadina M., Chiariello M., Chen E.H., Stancato L.F., Gutkind J.S., and O'Shea J.J. Importance of MKK6/p38 pathway for IL-12-induced STAT4 serine phosphorylation and transcriptional activity. *Blood*, **96**:1844-1852, 2000.
123. Arozarena I., Aaronson D.S., Sanz V., Ajenjo N., Matallanas D., Teramoto H., Iguishi T., Zabala J.S., Bustelo X.R., Gutkind J.S., and Crespo P. Ras-GRF-induced signaling and cellular transformation requires the participation of the GTPase cdc42. *J. Biol. Chem.*, *J. Biol. Chem.*, **275**: 26441-26448, 2000.
124. Hyun T., Yam A., Pece S., Xie X., Zhang J., Miki T., Gutkind J.S., and Li W. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. *Blood*, **96**:3560-3568, 2000.
125. Du Villard J.A., Wicker R., Crespo P., Russo D., Filetti S., Gutkind J.S., Sarasin A., and Suarez H.G. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation. *Oncogene*, **19**:4896-4905, 2000.
126. Fukuhara S. and Gutkind J.S. A new twist for the tumour suppressor hamartin. *Nature Cell Biol.*, **2**: E76-E78, 2000.

127. Fukuhara S., Marinissen M.J., Chiariello M., and Gutkind J.S. Signaling from G Protein-coupled receptors to ERK5/BMK 1 involves  $G\alpha_q$  and  $G\alpha_{12/13}$  families of heterotrimeric G proteins: Evidence for the existence of a novel Ras and Rho-independent pathway. *J. Biol. Chem.*, **275**: 21730-21736, 2000.
128. Sodhi A., Montaner S., Patel V., Zohar M., Bais C., Mesri E.A., and Gutkind J.S. The Kaposi's sarcoma associated Herpesvirus G protein-coupled receptor upregulates VEGF expression and secretion through MAPK and p38 pathways acting on HIF-1 $\alpha$ . *Cancer Research*, **60**:4873-4880, 2000.
129. Patel V., Ensley J.F., Gutkind J.S., and Yeudall W.A. Induction of apoptosis in head and neck squamous carcinoma cells by  $\gamma$ -irradiation and bleomycin is p53-independent. *Internatl. J. Cancer*, **88**:737-743, 2000.
130. Fukuhara S., Chikumi H., and Gutkind J.S. Leukemia-Associated Rho Guanine Nucleotide Exchange Factor (LARG) links heterotrimeric G proteins of the  $G_{12}$  family to Rho. *FEBS Letters*, **485**:183-188, 2000.
131. Pece S. and Gutkind J.S. Signaling from E-Cadherins to the MAPK pathway by the recruitment and activation of EGF receptors upon cell-cell contact formation. *J Biol Chem.*, **275**:41227-41233, 2000.
132. Marinissen M.J., Chiariello M., and Gutkind J.S. Regulation of gene expression by the small GTPase Rho through the ERK6 (p38 $\gamma$ ) MAP kinase pathway. *Genes Dev.*, **15**:535-553, 2001.
133. Patel V., Leethanakul C., and Gutkind J.S. New Approaches for the understanding of the molecular basis of oral cancer. *Crit. Rev. Oral Med.*, **12**:55-63, 2001.
134. Montaner S., Sodhi A., Pece S., Mesri E.A., and Gutkind J.S. The Kaposi's Sarcoma Associated Herpesvirus G Protein-Coupled Receptor promotes endothelial cell survival through the activation of Akt/PKB. *Cancer Res.*, **61**:2641-2648, 2001.
135. Dong F., Gutkind J.S., and Lerner A.C. Granulocyte colony-stimulating factor induces erk5 activation, which is differentially regulated by protein-tyrosine kinases and protein kinase C. Regulation of cell proliferation and survival. *J. Biol. Chem.*, **276**:10811-10816, 2001
136. Yuan P.X., Huang L.D., Jiang Y.M., Gutkind J.S., Manji H.K., and Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. *J. Biol. Chem.*, **276**:31674-31683, 2001.
137. Longenecker K.L., Lewis M.E., Chikumi H., Gutkind J.S., and Derewenda Z.S. Structure of the RGS-like domain from PDZ-RhoGEF linking heterotrimeric G protein-coupled signaling to Rho GTPases. *Structure (Cell Press)*, **9**:559-69, 2001.
138. Chiariello M., Marinissen M.J., and Gutkind J.S. Regulation of *c-myc* expression by PDGF through Rho GTPases. *Nature Cell. Biol.*, **3**:580-586, 2001.
139. Sodhi A., Montaner S., Miyazaki H., and Gutkind J.S. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1 $\alpha$  in ras V12 upregulation of VEGF. *Biochem. Biophys. Res. Commun.*, **287**:292-300, 2001
140. Knezevic V., Leethanakul C., Bichsel B.E, Worth J.M., Prabhu V.V., Gutkind J.S., Liotta L.A., Munson P.J., Petricoin III E.F., and Krizman D.B. Proteomic profiling of the cancer microenvironment by antibody microarrays. *Proteomics*, **10**:1271-8, 2001.
141. Segrelles C., Ruiz S., Perez P., Murga C., Santos M., Budunova I.V., Martinez J., Larcher F., Slaga T.J., Gutkind J.S., Jorcano J.L., and Paramio J.M. Functional roles of Akt signaling in mouse skin tumorigenesis. *Oncogene*, **21**:53-64. 2002.
142. Murga C., Zohar M., Teramoto H., and Gutkind J.S. Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF- $\kappa$ B. *Oncogene*, **21**:207-16, 2002.
143. Sakabe K., Teramoto H., Zohar M., Behbahani B., Miyazaki H., Chikumi H., and Gutkind J.S. Potent transforming activity of the small GTP-binding protein Rit in NIH 3T3 cells: Evidence for a role of a p38 $\gamma$  -dependent signaling pathway. *FEBS Lett.*, **511**:15-20, 2002

144. Katz B.Z., Miyamoto S., Teramoto H., Zohar M., Krylov D., Vinson C., Gutkind J.S., and Yamada K.M. Direct transmembrane clustering and cytoplasmic dimerization of focal adhesion kinase initiates its tyrosine phosphorylation. *Biochim. Biophys. Acta*, **1592**: 141-152, 2002.
145. Chen H.W., Chen X., Oh S.W., Marinissen M.J., Gutkind J.S., and Hou S.X. Mom identifies a receptor for the Drosophila JAK/STAT signal transduction pathway and encodes a protein distantly related to the mammalian cytokine receptor family. *Genes Dev.*, **16**:388-398, 2002.
146. Orsulic S., Li Y., Soslow R.A., Vitale-Cross L.A., Gutkind J.S., and Varmus H.E. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. *Cancer Cell*, **1**: 53-62, 2002.
147. Chikumi H., Fukuhara S., and Gutkind J.S. Regulation of G protein-linked guanine nucleotide exchange for Rho, PDZ-RhoGEF and LARG, by tyrosine phosphorylation: Evidence of a role for FAK. *J. Biol. Chem.*, **277**:12463-12473, 2002.
148. Chen H.W., Marinissen M.J., Oh S.W., Chen X., Melnick M., Perrimon N., Gutkind J.S., and Hou S.X. CKA, a novel multidomain protein, regulates the JUN N-terminal kinase signal transduction pathway in Drosophila. *Mol. Cell. Biol.*, **22**:1792-803, 2002.
149. Sanchez-Prieto R., Sanchez-Arevalo V.J., Servitja J.-M., and Gutkind J.S. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. *Oncogene*, **31**:974-979, 2002.
150. Regnaud K.L., Leteurtre E., Gutkind J.S., Gespach C.P., and Emami S. Activation of adenylyl cyclases, regulation of insulin status, and cell survival by G(alpha)olf in pancreatic beta-cells. *Am. J. Physiol.*, **282**:R870-880, 2002.
151. Patel V., Lahusen T., Sy T., Sausville E.A., Gutkind J.S., and Senderowicz A.M. Perifosine, a novel alkylphospholipid, induces p21<sup>(WAF1)</sup> expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. *Cancer Res.*, **62**:1401-1409, 2002.
152. Patel V., Aldridge K., Ensley J.F., Odell E., Boyd A., Jones J., Gutkind J.S., and Yeudall W.A. Laminin-gamma2 overexpression in head-and-neck squamous cell carcinoma. *Internatl. J. Cancer*, **99**:583-588, 2002.
153. Machado de Sousa S.O., Mesquita R.A, Pinto Jr D.S., and Gutkind J.S. Immunolocalization of c-Fos and c-Jun in human oral mucosa and in oral squamous cell carcinoma. *J. Oral Pathol.*, **31**:78-81, 2002.
154. Choi Y., Zhang J., Murga C., Yu H., Koller E., Monia B.P., Gutkind J.S., and Li W. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. *Oncogene*, **21**:5289-5300, 2002.
155. Chikumi H., Vazquez-Prado J., Servitja J.-M., Miyazaki H., and Gutkind J.S. Potent activation of RhoA by Gq and Gq-coupled receptors. *J. Biol. Chem.*, **277**:27130-27134, 2002.
156. Perrot V., Vázquez-Prado J., and Gutkind J.S. Plexin B Regulates Rho through the Guanine Nucleotide Exchange Factors LARG and PDZ-RhoGEF. *J. Biol. Chem.*, **277**:43115-43120, 2002.
157. Patel V., Lahusen T., Leethanakul C., Igishi T., Kremer M., Quintanilla-Martinez L., Ensley J.F., Sausville E.A., Gutkind J.S., and Senderowicz A.M. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27KIP1. *Clin. Cancer Res.* **8**:3549-3560, 2002.
158. Aurandt J., Vikis H.G., Gutkind J.S., Ahn N., and Guan K.-L. The semaphorin receptor plexin-B1 signals through a direct interaction with the Rho-specific nucleotide exchange factor, LARG. *Proc. Natl. Acad. Sci.*, **99**:12085-12090, 2002.
159. Guo Y.S., Cheng J.Z., Jin G.F., Gutkind J.S., Hellmich M.R., and Townsend C.M. Jr. Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through

- multiple signaling pathways. Evidence for involvement of ERK5 kinase and transactivation of EGF receptor. *J. Biol. Chem.*, **277**:48755-48763, 2002.
160. Leethanakul C., Knezevic V., Patel V., Amornphimoltham P., Gillespie J., Shillitoe E.J., Emkoe P., Park M.H., Emmert-Buck M.R., Strausberg R.L., Krizman D.B., and Gutkind J.S. Gene Discovery in Oral Squamous Cell Carcinoma through the Head and Neck Cancer Genome Anatomy Project: Confirmation by Microarray Analysis. *Oral Oncol.*, **39**:248-258, 2003.
  161. Montaner S., Sodhi A., Molinolo A., Bugge T.H., Sawai E.T., He Y., Li Y., Ray P.E., and Gutkind J.S. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. *Cancer Cell*, **3**:23-36, 2003.
  162. Servitja J.-M., Masgrau R., Pardo R., Sarri E., von Eichel-Streiber C., Gutkind J.S., and Picatoste F. Metabotropic glutamate receptors activate phospholipase D in astrocytes through a protein kinase C-dependent and Rho-independent pathway. *Neuropharmacol.*, **44**:171-80, 2003.
  163. Nishigaki K., Thompson D., Yugawa T., Rulli K., Hanson C., Cmarik J., Gutkind J.S., Teramoto H., and Ruscetti S. Identification and characterization of a novel Ste-20/GCK-related kinase, PAP kinase (PAPK). *J. Biol. Chem.*, **278**:13520-13530, 2003.
  164. Sriuranpong V., Park J.I., Amornphimoltham P., Patel P., Nelkin B.D., and Gutkind J.S. EGFR-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the IL6/gp130 cytokine system. *Cancer Research*, **63**:2948-2956, 2003.
  165. Teramoto H., Malek R.L., Behbahani B., Castellone M.D., Lee N.L., and Gutkind J.S. Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes. *Oncogene*, **22**:2689-2697, 2003.
  166. Pedersen T.X., Leethanakul C., Patel V., Mitola D., Lund L.R., Dano K., Johnsen M., Gutkind J.S., and Bugge T.H. Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma. *Oncogene*, **22**:3964-3976, 2003.
  167. Servitja J.M., Marinissen M.J., Sodhi A., Bustelo X.R., and Gutkind J.S. Rac1 function is required for Src-induced transformation: Evidence of a role for Tiam1 and Vav2 in Rac activation by Src. *J. Biol. Chem.*, **278**:34339-34346, 2003.
  168. Monje P., Marinissen M.J., and Gutkind J.S. The phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by ERK mediates the transcriptional activation of AP-1 and cellular transformation induced by PDGF. *Mol. Cell. Biol.*, **23**:7030-7043, 2003.
  169. Marinissen M.J., Servitja J.-M., Offermanns S., Simon M.I., and Gutkind J.S. The thrombin receptor PAR-1 signals through G<sub>q</sub> and G<sub>13</sub>-initiated MAPK cascades regulating c-Jun expression to induce cell transformation. *J. Biol. Chem.*, **278**:46814-46825, 2003.
  170. Iavarone C., Catania A., Marinissen M.J., Visconti R., Acunzo M., Tarantino C., Carlomagno M.S., Bruni C.B., Gutkind J.S., and Chiariello M. PDGF controls c-myc expression through a JNK- and AP-1-dependent signaling pathway. *J. Biol. Chem.*, **278**:50024-50030, 2003.
  171. Chikumi H., Barac A., Behbahani B., Gao Y., Teramoto H., Zheng Y., and Gutkind J.S. Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their *in vivo* Rho GEF activity and transforming potential. *Oncogene*, **23**:233-240, 2004.
  172. Barac A., Basile J., Vazquez-Prado J., Gao Y., Zheng Y., and Gutkind J.S. Direct interaction of PAK4 with PDZ-RhoGEF, a G protein-linked Rho guanine exchange factor. *J. Biol. Chem.*, **279**:6182-6189, 2004.
  173. Sodhi A., Montaner S., and Gutkind J.S. Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's Sarcomagenesis? *Faseb J.*, **18**:422-427, 2004.

174. Sodhi A., Montaner S., Patel V., Román J.G., Li Y., Sausville E.A., Sawai E.T., and Gutkind J.S. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. *Proc. Natl. Acad. Sci. U.S.A.*, **101**:4821-4826, 2004.
175. Amornphimoltham P., Sriuranpong V., Patel V., Benavides F., Conti C.J., Sauk J., Sausville E.A., Molinolo A.A., and Gutkind J.S., Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01, *Clin. Cancer Research*, **10**:4029-4037, 2004.
176. Sriuranpong V., Mutirangura A., Gillespie J.W., Patel V., Amornphimoltham P., Molinolo A.A., Kerekhanjanarong V., Supanakorn S., Supiyaphun P., Rangdaeng S., Voravud N., and Gutkind J.S. Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and cDNA microarrays. *Clin. Cancer Research*, **10**:4944-4958, 2004.
177. Basile J.R., Barac A., Zhu T., Guan K.-L., and Gutkind J.S. Class IV Semaphorins promote angiogenesis by stimulating Rho-initiated pathways through Plexin-B, *Cancer Research*, **64**:5212-5224, 2004.
178. Oliva J.L., Zarich N., Martínez J.R., Castrillo A., Azañedo M., García-Vargas S., Juarranz A., Boscá L., Gutkind J.S., and Rojas J.M. The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH3T3 cells but not of H-Ras. *J. Biol. Chem*, **279**:33480-33491, 2004.
179. Rosenfeldt H., Vazquez-Prado J., and Gutkind J.S. P-Rex2, a novel PI-3-Kinase sensitive Rac exchange factor. *FEBS Lett.*, **572**:167-71, 2004.
180. Jeon G.A., Lee J.-S., Patel V., Gutkind J.S., Thorgeirsson S.S., Kim E.C., Amornphimoltham P., and Park M.H. Global gene expression profiles of human head and neck squamous carcinoma cells, *Internatl. J. Cancer*, **112**:249-258, 2004.
181. Kesavapany S., Amin N., Zheng Y.-L., Nijhara R., Jaffe H., Sihag R., Gutkind J.S., Takahashi S., Kulkarni A., Grant P., and Pant H.C. p35/Cdk5 phosphorylation of RasGRF2 mediates Rac-dependent ERK1/2 activity, altering RasGRF2 and MAP1b distribution in neurons. *J. Neurosci.*, **24**:4421-4433, 2004.
182. Curino A., Patel V., Schnack-Nielsen B., Iskander A.J., Ensley J.F., Yoo G., Holsinger C., Myers J.N., Shillitoe E.J., Molinolo A.A., Gutkind J.S., and Bugge T.H. Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. *Oral Oncol.*, **40**:1026-1032, 2004.
183. Montaner S., Sodhi A., Servitja J.-M., Ramsdell A.K., Barac A., Sawai E.T., and Gutkind J.S. The small GTPase Rac1 links the Kaposi's Sarcoma Herpesvirus vGPCR to NF- $\kappa$ B-mediated transcription and secretion of IL-6 and paracrine neoplasia. *Blood*, **104**:2903-2911, 2004.
184. Vitale-Cross L., Amornphimoltham P., Fisher G., Molinolo A.A., and Gutkind J.S. Conditional expression of K-ras in an epithelial compartment that includes the stem-cells is sufficient to promote squamous cell carcinogenesis. *Cancer Res.*, **64**:8804-8807, 2004.
185. Marinissen M.J., Chiariello M., Tanos T., Bernard O., Narumiya S., and Gutkind J.S. The small GTP-binding protein RhoA regulates c-Jun by a ROCK-JNK signaling axis, *Mol. Cell*, **14**:29-41, 2004.
186. Vazquez-Prado J., Miyazaki H., Castellone M.D., Teramoto H., and Gutkind J.S. Chimeric G $\alpha_{12}$ /G $\alpha_{13}$  proteins reveal the structural requirements for the binding and activation of RGL-containing Rho GEFs by G $\alpha_{13}$ . *J. Biol. Chem.*, **279**:54283-54290, 2004.
187. Baker H., Patel V., Molinolo A.A., Myers J.N., El-Naggar A.K., Gutkind J.S., and Hancock W.S. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass-spectrometry, *Oral Oncol.*, **41**:183-199, 2005.

188. Teramoto H., Castellone M.D., Malek R.L., Behbahani B., Letwin N., Gutkind J.S., and Lee N.H. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12, *Oncogene*, **24**:489-501, 2005.
189. Brantley E., Patel V., Stinson S.F., Trapani V., Hose C.D., Ciolino H.P., Yeh G.C., Gutkind J.S., Sausville E.A., and Loaiza-Perez A.I. The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells. *Anticancer Drugs*, **16**:137-143, 2005.
190. Patel V., Ramesh A., Traicoff J.L., Baibakov G., Emmert-Buck M.R., Gutkind J.S., and Knezevic V. Profiling EGFR activity in head and neck squamous cell carcinoma by using a novel layered membrane Western blot technology. *Oral Oncol.*, **41**:503-508, 2005.
191. Tanos T., Marinissen M.J., Coluccio Leskow F., Hochbaum D., Martinetto H., Gutkind J.S., and Coso O.A. Phosphorylation of c-Fos by members of the p38 MAPK family: Role in the AP-1 response to UV. *J. Biol. Chem.*, **280**:18842-18852, 2005.
192. Yeudall W.A., Miyazaki H., Ensley J.F., Cardinali M., Gutkind J.S., Patel V. Uncoupling of Epidermal Growth Factor-dependent proliferation and invasion in a model of squamous carcinoma progression. *Oral Oncol.*, **41**:698-708, 2005.
193. List K., Szabo R., Molinolo A., Sriuranpong V., Redeye V., Burke B., Murdock T., Nielsen B.S., Gutkind J.S., and Bugge T. H. Deregulated matriptase proteolysis causes *ras*-independent multistage carcinogenesis and promotes *ras*-mediated malignant transformation. *Genes Dev.*, **19**:1934-1950, 2005.
194. Basile J.R., Afkhami T., and Gutkind J.S. Semaphorin 4D/Plexin-B1 Induces Endothelial Cell Migration through the Activation of PYK2, Src and the PI3K-Akt pathway. *Mol. Cell. Biol.*, **25**:6889-6898, 2005.
195. Monje P., Hernández-Losa J., Castellone M.D., Lyons R., and Gutkind J.S. Regulation of the transcriptional activity of c-Fos by ERK: A novel role for the prolyl-isomerase Pin1. *J. Biol. Chem.*, **280**:35081-35084, 2005.
196. Amornphimoltham P., Patel V., Sodhi A., Nikitakis N.G., Sauk J.J., Sausville E.A., Molinolo A.A., and Gutkind J.S. mTOR, a molecular target in squamous cell carcinomas of the head and neck. *Cancer Research*, **65**:9953-9961, 2005.
197. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., and Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a novel Gs-axin- $\beta$ -catenin signaling axis. *Science*, **310**:1504-1510, 2005.
198. Montaner S., Sodhi A., Ramsdell A.K., Martin D., Hu J., Sawai E.T., and Gutkind J.S., The Kaposi's sarcoma associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. *Cancer Research.*, **66**:168-174, 2006.
199. Miyazaki H., Patel V., Wang H., Ensley J.F., Gutkind J.S., Yeudall W.A. Growth factor-sensitive molecular targets identified in primary and metastatic head and neck squamous cell carcinoma using microarray analysis. *Oral Oncol.*, **42**:240-256, 2006.
200. Kaur S., Castellone M.D., Bedell V.M., Konar M., Gutkind J.S., and Ramchandran R. Robo4 signaling in endothelial cells implies attraction guidance mechanisms. *J. Biol. Chem.*, **281**: 1347-1356, 2006.
201. Raimondi R.R., Vitale-Cross L., Amornphimoltham P., Gutkind J.S., and Molinolo A.A. Rapid development of salivary gland carcinomas upon conditional expression of K-ras driven by the cytokeratin 5 promoter. *Amer. J. Pathol.*, **168**:1654-1565, 2006.
202. Kehat I., Heinridh R., Ofer B-I., Miyazaki H., Gutkind J.S., and Aronheim A. Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation. *Cardiovasc Res.* **70**:543-554, 2006.
203. Gu J., Wu X., Dong Q., Romeo M.J., Lin X., Gutkind J.S., and Berman D.M. A nonsynonymous single-nucleotide polymorphism in the PDZ-Rho guanine nucleotide exchange factor (Ser1416Gly) modulates the risk of lung cancer in Mexican Americans. *Cancer*, **106**:2716-2724, 2006.

204. Basile J.R., Castilho R.M., Williams V.P., and Gutkind J.S. Semaphorin4D provides a link between axon guidance processes and tumor-induced angiogenesis, *Proc. Natl. Acad. Sci. U.S.A.*, **103**:9017-9022, 2006.
205. Gelbard A., Garnett C.T., Abrams S.I., Patel V., Gutkind J.S., Palena C., Tsang K.-Y., Schlom J., and Hodge J.W. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. *Clin. Cancer Research*, **12**:1897-1905, 2006.
206. Gavard J. and Gutkind J.S. VEGF controls endothelial cell permeability by promoting the  $\beta$ -arrestin-dependent endocytosis of VE-cadherin. *Nature Cell Biol.*, **11**:1223-1234, 2006.
207. Sodhi A., Chaisuparat R., Hu J., Ramsdell A.K., Manning B.D., Sausville E.A., Sawai E.T., Molinolo A., Gutkind J.S., and Montaner S. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's Sarcoma Associated Herpesvirus G Protein-Coupled Receptor. *Cancer Cell*, **10**:133-143, 2006.
208. Squarize C.H., Castilho R.M., Sriuranpong V., Pinto Jr. D.C., and Gutkind J.S. A molecular cross-talk between the NF $\kappa$ B and STAT3 signaling pathways in head and neck squamous cell carcinoma. *Neoplasia*, **8**:733-746, 2006.
209. Rosenfeldt H., Castellone M.D., Randazzo P.A., and Gutkind J.S. Rac inhibits thrombin-induced Rho activation: Evidence of a Pak-dependent GTPase crosstalk. *J. Cell Signal.*, **1**:8, 2006.
210. Tan W., Martin D., and Gutkind J.S. The G $\alpha_{13}$ -Rho signaling axis is required for SDF-1 induced migration through CXCR4. *J. Biol. Chem.*, **281**:39542-39549, 2006.
211. Yu X., Munge B., Patel V., Jensen G., Bhirde A., Gong J.D., Kim S., Gillespie J., Gutkind J.S., Papadimitrakopoulos F., and Rusling J.F. Carbon nanotube amplification strategies for highly sensitive immunosensing of cancer biomarkers in serum and tissue. *J. Amer. Chem. Soc.*, **128**:11199-11205, 2006.
212. Teramoto H., Miwa H., Patel V., Letwin N., Castellone M.D., Imai N., Shikami M., Imamura A., Gutkind J.S., Nitta M., Lee N.H. Gene expression changes in a patient presenting nonleukaemic nasal granulocytic sarcoma to acute myelogenous leukaemia using 40 K cDNA microarray. *Clin. Lab. Haematol.*, **28**:262-266, 2006.
213. Sanchez V.M., Crespo A., Gutkind J.S., and Turjanski A.G. Investigation of the catalytic mechanism of farnesyl pyrophosphate synthase by computer simulation. *J. Phys. Chem.*, **110**:18052-18057, 2006.
214. Kesavapany S., Pareek T.K., Zheng Y.L., Amin N., Gutkind J.S., Ma W., Kulkarni A.B., Grant P., and Pant H.C. Neuronal nuclear organization is controlled by cyclin-dependent kinase 5 phosphorylation of Ras guanine nucleotide releasing factor-1. *Neurosignals*, **15**:157-173, 2006.
215. Miyazaki H., Patel V., Wang H., Edmunds R.K., Gutkind J.S., and Yeudall W.A. Down-regulation of CXCL5 inhibits squamous carcinogenesis. *Cancer Research*, **66**: 4279-4284, 2006.
216. Touge H., Chikumi H., Igishi T., Kurai J., Makino H., Tamura Y., Takata M., Yoneda K., Nakamoto M., Suyama H., Gutkind J.S., and Shimizu E. Diverse activation states of RhoA in human lung cancer cells: Contribution of G protein coupled receptors. *Int. J. Oncol.*, **30**:709-715, 2007.
217. Basile J.R., Holmbeck K., Bugge T.H., and Gutkind J.S. MT1-MMP controls tumor-induced angiogenesis through the release of Semaphorin 4D. *J. Biol. Chem.*, **282**:6899-6905, 2007.
218. Castilho R.M., Squarize C.H., Patel V., Millar S.E., Zheng Y., Molinolo A., and Gutkind J.S. Requirement of Rac1 distinguishes follicular from interfollicular epithelial stem cells. *Oncogene*, **26**:5078-5085, 2007.
219. Turjanski A.G., Vaqu e J.P., and Gutkind J.S. MAP Kinases and the Control of Nuclear Events. *Oncogene*, **26**:3240-3253, 2007.

220. Montero-Girard G., Vanzulli S.I., Cerliani J.P., Bottino M.C., Bolado J., Vela J., Becu-Villalobos D., Benavides F., Gutkind J.S., Patel V., Molinolo A., and Lanari C. Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. *Breast Cancer Res.*, **9**: R22, 2007.
221. Kupferman M.E., Patel V., Sriuranpong V., Amornphimoltham P., Jasser S.A., Mandal M., Zhou G., Wang J., Coombes K., Multani A., Pathak S., Gutkind J.S., and Myers J.N. Molecular analysis of anoikis resistance in oral cavity squamous cell carcinoma. *Oral Oncol.*, **43**:440-454, 2007.
222. Patel V., Rosenfeldt H., Lyons R., Servitja J.-M., Bustelo X.R., Siroff M., and Gutkind J.S. Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR-Vav2 signaling axis involved in cell invasion. *Carcinogenesis* **28**:1145-1152, 2007.
223. Hernandez-Negrete I., Carretero-Ortega J., Rosenfeldt H., Hernandez-Garcia R., Calderon-Salinas J.V., Reyes-Cruz G., Gutkind J.S., and Vazquez-Prado J. P-Rex1 links mTOR signaling to Rac activation and cell migration. *J. Biol. Chem.*, **282**:23708-23715, 2007.
224. Honjo Y., Bian Y., Kawakami K., Molinolo A., Longenecker G., Boppana R., Larsson J., Karlsson S., Gutkind J.S., Puri R.K., and Kulkarni A.B. TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma. *Cell Cycle*, **6**:1360-1366, 2007.
225. Liu H., Fergusson M.M., Castilho R.M., Liu J., Liu C., Chen J., Malide D., Rovira I.I., Schimel D., Kuo K.J., Gutkind J.S., Hwang P.M., and Finkel T. Augmented Wnt signaling in a mammalian model of accelerated aging. *Science*, **317**:803-806, 2007.
226. Molinolo A.A., Hewitt S., Amornphimoltham P., Keelawat S., Rangaeng S., Meneses Garcia A., Raimondi A.R., Jufe R., Itoiz M., Gao Y., Saranath D., Kaleebi G.S., Yoo G.H., Leak L., Myers E.M., Shintani S., Wong D., Massey H.D., Yeudall W.A., Lonardo F., Ensley J., and Gutkind J.S. Dissecting the Akt/mTOR signaling network: Emerging results from the Head and Neck Cancer Tissue Array Initiative. *Clin. Cancer Research*, **13**:4964-4973, 2007.
227. Wagenaar-Miller R.A., Engelholm L.H., Gavard J., Yamada S.S., Gutkind J.S., Behrendt N., Bugge T.H., and Holmbeck K. Complementary roles of intracellular and pericellular collagen degradation pathways *in vivo*. *Mol. Cell. Biol.*, **27**:6309-6322, 2007.
228. Kesavapany S., Patel V., Zheng Y.L., Pareek T.K., Bjelogric M., Albers W., Amin N., Jaffe H., Gutkind J.S., Strong M.J., Grant P., and Pant H.C. Inhibition of Pin1 Reduces Glutamate-induced perikaryal accumulation of phosphorylated neurofilament-H in neurons. *Mol. Biol. Cell.*, **18**:3645-3655, 2007.
229. Martin M.J., Tanos T.B., Garcia A.B., Martin D., Gutkind J.S., Coso O.A., Marinissen M.J. The G $\alpha$  12/13 family of heterotrimeric G proteins and the small GTPase RhoA link the Kaposi sarcoma-associated herpes virus-G protein coupled receptor to heme oxygenase-1 expression and tumorigenesis. *J. Biol. Chem.*, **282**:34510-34524, 2007.
230. Basile J.R., Gavard J., Gutkind J.S. Plexin-B1 utilizes RHOA and ROK to promote the integrin-dependent activation of AKT and ERK, and endothelial cell motility. *J. Biol. Chem.*, **282**:34888-34895, 2007.
231. Wirth A., Benyó Z., Lukasova M., Leutgeb B., Wettschureck N., Gorbey S., Örsy P., Horváth B., Maser-Gluth C., Greiner E., Lemmer B., Schütz G., Gutkind S., and Offermanns S. G12-G13–LARG–mediated signaling in vascular smooth muscle is required for salt-induced hypertension. *Nature Medicine*, **14**:64-68, 2008.
232. Liu S., Wang H., Currie B.M., Molinolo A., Leung H.J., Moayeri M., Basile J.R., Alfano R.W., Gutkind J.S., Frankel A.E., Bugge T.H., and Leppla S.H. Matrix metalloproteinase-

- activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. *J. Biol. Chem.*, **283**:529-540, 2008.
233. Gavard J., Patel V., and Gutkind J.S. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. *Dev. Cell*, **14**:25-36, 2008.
234. Wolf J., Palmby T.R., Gavard J., Williams B.O., and Gutkind J.S. Multiple PPPS/TP motifs act in a combinatorial fashion to transduce Wnt Signaling through LRP6. *FEBS Lett.*, **582**:255-261, 2008.
235. Martin D., Galisteo R., Ji Y., Montaner S., and Gutkind J.S. A NF- $\kappa$ B gene expression signature contributes to Kaposi's Sarcoma Virus vGPCR-induced direct and paracrine neoplasia. *Oncogene*, **27**:1844-1852, 2008.
236. Galan-Moya E.M., Hernandez-Losa J., Aceves Luquero C.I., de la Cruz-Morcillo M.A., Ramírez-Castillejo C., Callejas-Valera J.L., Arriaga A., Fernandez Aranburo A, Ramón y Cajal S., Gutkind J.S., and Sánchez-Prieto R. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: implications in cisplatin based therapy. *Int. J. Cancer*, **122**: 289-297, 2008.
237. Amornphimoltham P., Patel V., Leelahavanichkul K., Abraham R.T., and Gutkind J.S. A retro-inhibition approach reveals a tumor cell-autonomous therapeutic response to rapamycin in head and neck squamous cell carcinomas. *Cancer Research*, **68**:1144-1153, 2008.
238. Patel V., Hood B.L., Molinolo A.A., Lee N.H, Conrads T.P., Braisted J.C., Krizman D.B., Veenstra T.D., Gutkind J.S. Proteomic analysis of laser-captured paraffin embedded tissues: A molecular portrait of head and neck cancer progression. *Clin. Cancer Research*, **14**:1002-1014, 2008.
239. Gómez-Román J.J., Garay G.O., Saenz P., Escuredo K., Ibayondo C.S., Junquera C., Gutkind J.S., Belaustegui-Trías C., Simón L., Martínez A., Fernández-Luna J.L., Val-Bernal J.F. Plexin B1 is downregulated in renal neoplasmas and modulates cell growth. *Trans. Res.*, **151**:134-140, 2008.
240. Zhou G., Xie T-X., Zhao M., Jasser S.A., Younes M.N., Sano D., Lin J., Kupferman M.E., Santillan A.A., Patel V., Gutkind J.S., El-Naggar A.K., Emberley E.D., Watson P.H., Matsuzawa S-I., Reed J.C., and Myers J.N. Reciprocal negative regulation between S100A7/psoriasis and bold beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. *Oncogene*, **25**:3527-3538, 2008.
241. Sausville J., Molinolo A.A., Cheng X., Frampton J., Takebe N., Gutkind J.S., and Feldman R.A. RCAS/SCL-TVA animal model allows targeted delivery of PyMT oncogene to vascular endothelial progenitors in vivo, and results in rapid hemangioma. *Clin. Cancer Research*, **14**:3948-3955, 2008.
242. Turjanski A.G., Gutkind J.S., Best R.B., and Hummer G. Binding-induced folding of a natively unstructured transcription factor. *PLoS Computational Biology*, **4**:e1000060.
243. Lyons J.G., Patel V., Roue1 N., Fok S.Y., Soon L.L., Halliday J.M., and Gutkind J.S. Snail expression in oral keratinocytes up-regulates pro-inflammatory mediators and inhibits terminal differentiation. *Cancer Research*, **68**:4525-4530, 2008
244. Sun C., Dobi A., Mohamed A., Li H., Thangapazham R.L., Furusato B., Shaheduzzaman S., Tan S.H., Vaidyanathan G., Whitman E., Hawksworth D.J., Chen Y., Nau M., Patel V., Vahey M., Gutkind J.S., Sreenath T., Petrovics G., Sesterhenn I.A., McLeod D.G., Srivastava S. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. *Oncogene* **27**:5348-5353, 2008.
245. Yamaza T., Miura Y., Bi Y., Liu Y., Akiyama K., Sonoyama W., Patel V., Gutkind J.S., Young M., Gronthos S., Le A., Wang C.Y., Chen W., and Shi S. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. *PLoS ONE.*, **3**:e2615, 2008.

246. Squarize C.H., Castilho R.M., and Gutkind J.S. Chemoprevention of experimental Cowden's Disease by mTOR inhibition with rapamycin. *Cancer Research*, **68**:7066-7072.
247. Paccione R.J., Miyazaki H., Patel V., Waseem A., Gutkind J.S., Zehner Z.E., and Yeudall W.A. Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility. *Mol. Cancer. Ther.* **7**:2894-2903, 2008.
248. Gavard J. and Gutkind J.S. Protein Kinase C-related Kinase and ROCK are required for thrombin-induced endothelial cell permeability downstream from G $\alpha_{12/13}$  and G $\alpha_{11/q}$ . *J. Biol. Chem.*, **283**:29888-29896, 2008.
249. Schneider A., Younis R.H., and Gutkind J.S. Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. *Neoplasia* **10**:1295-1302, 2008.
250. Tan W., Palmby T.R., Gavard J., Amornphimoltham P., Zheng Y, and Gutkind J.S. An essential role for Rac1 in endothelial cell function and vascular development. *FASEB J.*, **22**:1829-1838, 2008.
251. Amornphimoltham A., Leelahavanichkul K., Molinolo A.A., Patel V., and Gutkind J.S. Inhibition of mTOR by rapamycin causes the regression of carcinogen-induced skin tumor lesions. *Clin. Cancer Research*, **14**:8094-8101, 2008.
252. Czerninski R., Amornphimoltham P., Patel V., Molinolo A.A., and Gutkind J.S. Targeting mTOR by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. *Cancer Prevention Research*, **2**:27-36, 2009.
253. Wang H., Patel V., Miyazaki H., Gutkind J.S., and Yeudall W.A. Role for EPS8 in squamous carcinogenesis. *Carcinogenesis*, **30**:165-174, 2009.
254. Bhirde A.A., Patel V., Gavard J., Zhang G., Sousa A.A., Masedunskas A., Leapman R.D., Weigert R., Gutkind J.S., and Rusling J.F. Targeted killing of cancer cells *in vivo* and *in vitro* with EGF-directed carbon nanotube-based drug delivery. *Am. Chem. Soc. Nano*, **3**:307-316, 2009.
255. Castellone M.D., De Falco V., Rao D.M., Bellelli R., Muthu M., Basolo F., Fusco A., Gutkind J.S., and Santoro M. The  $\beta$ -catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. *Cancer Res.* **69**:1867-1876, 2009.
256. Munge B.S., Krause C.E., Malhotra R., Patel V., Gutkind J.S., and Rusling J.F. Electrochemical immunosensors for interleukin-6. Comparison of carbon nanotube forest and gold nanoparticle platforms. *Electrochem. Commun.* **11**:1009-1012, 2009.
257. Mani V., Chikkaveeraiah B.V., Patel V., Gutkind J.S., Rusling J.F. Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film electrodes and multienzyme-particle amplification. *Am. Chem. Soc. Nano*, **3**:585-594, 2009.
258. Gavard J., Hou X., Qu Y., Masedunskas A., Martin D., Weigert R., Li X., and Gutkind J.S. A Role for a CXCR2/PI3K signaling axis in acute and chronic vascular permeability. *Mol. Cell Biol.*, **29**:2469-2480, 2009.
259. Sako K., Fukuhara S., Minami T., Hamakubo T., Song H., Kodama T., Fukamizu A., Gutkind J.S., Koh G.Y., and Mochizuki N. Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase/AKT-dependent activation of myocyte enhancer factor 2. *J. Biol. Chem*, **284**:5592-5601, 2009.
260. Cheong S.C., Chandramouli G.V., Saleh A., Zain R.B., Lau S.H., Sivakumaren S., Pathmanathan R., Prime S.S., Teo S.H., Patel V., and Gutkind J.S. Gene expression in human oral squamous cell carcinoma is influenced by risk factor exposure. *Oral Oncol.*, **45**:712-719, 2009.
261. Martin D., Galisteo R., Gutkind J.S. CXCL8/IL8 stimulates VEGF expression and the autocrine activation of VEGFR2 in endothelial cells by activating NF $\kappa$ B through the CBM (Carma3/Bcl10/Malt1) complex. *J. Biol. Chem.*, **284**:6038-6042, 2009.

262. Turjanski A.G., Hummer G., and Gutkind J.S. How mitogen-activated protein kinases recognize and phosphorylate their targets: A QM/MM study. *J. Amer. Chem. Soc.*, **131**:6141-6148, 2009.
263. Raimondi A.R., Molinolo A., and Gutkind J.S. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. *Cancer Research*, **69**:4159-4166, 2009.
264. Guzmán-Hernández M.L., Vázquez-Macías A., Carretero-Ortega J., Hernández-García R., García-Regalado A., Hernández-Negrete I., Reyes-Cruz G., Gutkind J.S., Vázquez-Prado J. Differential inhibitor of G $\beta$  $\gamma$ -signaling to AKT and ERK derived from Phosducin-like protein: Effect on sphingosine-1-phosphate-induced endothelial cell migration and *in vitro* angiogenesis. *J. Biol. Chem.*, **284**:18334-188346, 2009.
265. Bian Y., Terse A., Du J., Hall B., Molinolo A., Zhang P., Chen W., Flanders K.C., Gutkind J.S., Wakefield L.M., and Kulkarni A.B. Progressive tumor formation in mice with conditional deletion of TGF- $\beta$  signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. *Cancer Research*, **69**:5918-5926, 2009.
266. Bhirde A.A., Sousa A.A., Patel V., Azari A.A., Gutkind J.S., Leapman R.D. and Rusling J.F. Single-molecule imaging and quantitation of a platinum-based drug attached to single-wall carbon nanotubes. *Nanomedicine* **4**:763-772, 2009.
267. Chikkaveeraiah B.V., Bhirde A., Malhotra R., Patel V., Gutkind J.S., Rusling J.F. Single-wall carbon nanotube forest arrays for immunoelectrochemical measurement of four protein biomarkers for prostate cancer. *Anal Chem* **81**:9129-9134, 2009.
268. Castilho R.M., Squarize C.H., Chodosh L.A., Williams B.O., and Gutkind J.S. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. *Cell Stem Cell*, **5**:279-289, 2009.
269. Gonzalez-Pardo V., Martin D., Gutkind J.S., Verstuyf A., Bouillon R., de Boland A.R., and Boland R.L. 1 $\alpha$ ,25-dihydroxyvitamin D3 and its TX527 analog inhibit the growth of endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein-coupled receptor *in vitro* and *in vivo*. *Endocrinology*, **151**:23-31, 2010.
270. Malhotra R., Patel V., Vaqué J.P., Gutkind J.S., and Rusling J.F. Ultrasensitive electrochemical immunosensor for oral cancer biomarker IL-6 using carbon nanotube forest electrodes and multilabel amplification. *Anal Chem.* **82**:3118-3123, 2010.
271. Sakurai A., Gavard J., Annas-Linhares Y., Basile J.R., Amornphimoltham P., Palmby T.R., Yagi H., Zhang F., Randazzo P.A., Li X., Weigert R., and Gutkind J.S. Semaphorin 3E initiates antiangiogenic signaling through Plexin-D1 by regulating Arf6 and R-Ras. *Mol. Cell Biol.*, **30**:3086-98, 2010.
272. Wang H., Teh M.T., Ji Y., Patel V., Firouzabadian S., Patel A.A., Gutkind J.S., and Yeudall W.A. EPS8 upregulates FOXM1 expression, enhancing cell growth and motility. *Carcinogenesis*, **31**:1132-41, 2010.
273. Castilho R.M., Squarize C.H., Leelahavanichkul K., Zheng Y., Bugge T., and Gutkind J.S. Rac1 is required for epithelial stem cell function during dermal and oral mucosal wound healing but not for tissue homeostasis in mice. *PLoS ONE*, **5**: e10503, 2010.
274. Squarize C.H., Castilho R.M., Bugge T., and Gutkind J.S. Accelerated wound healing by mTOR activation in genetically defined mouse models. *PLoS ONE*, **5**: e10643, 2010.
275. Weller M.L., Amornphimoltham P., Schmidt M., Wilson P.A., Gutkind J.S., and Chiorini J.A. Epidermal growth factor receptor is a receptor for adeno-associated virus serotype 6. *Nature Medicine*, **16**:662-664, 2010.
276. Abrahao A.C., Castilho R.M., Squarize C.H., Molinolo A.A., Santos-Pinto D.D. Jr, and Gutkind J.S. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. *Oral Oncol.*, **46**:880-887, 2010.
277. Hou X., Kumar A., Lee C., Wang B., Arjunan P., Dong L., Maminishkis A., Tang Z., Li Y., Zhang F., Zhang S.-Z, Wardega P., Chakrabarty S., Liu B., Wu Z., Colosi P., Fariss R.N.,

- Lennartsson J., Nussenblatt R., Gutkind J.S., Cao Y., and Li X. PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets. *Proc. Natl. Acad. Sci. U.S.A.*, **107**:12216-12221, 2010.
278. Facchinetti M.M., Gandini N.A., Fermento M.E., Sterin-Speziale N.B., Ji Y., Patel V., Gutkind J.S., Rivadulla M.G., Curino A.C. The expression of sphingosine kinase-1 in head and neck carcinoma. *Cells Tissues Organs*, **192**:314-324, 2010.
279. Knox S.M., Lombaert M. A., Reed X., Vitale-Cross L., Gutkind J.S. and Hoffman M.P. Parasympathetic innervation maintains epithelial progenitor cells during salivary organogenesis. *Science*, **329**:1645-1647, 2010.
280. Bhirde A.A., Patel S., Sousa A.A., Patel V., Molinolo A.A., Ji Y., Leapman R.D., Gutkind J.S., and Rusling J.F. Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. *Nanomedicine*, **5**:1535-1546, 2010.
281. Sosa M.S., Lopez-Haber C., Yang C., Wang H., Lemmon M.A., Busillo J.M., Luo J., Benovic J.L., Klein-Szanto A., Yagi H., Gutkind J.S., Parsons R.E., and Kazanietz M.G. Identification of the Rac-GEF P-REX1 as an essential mediator of ErbB signaling in breast cancer. *Mol. Cell*, **40**:877-892, 2010.
282. Suyarnsestakorn C., Thanasupawat T., Leelahavanichkul K., Gutkind J.S., and Mutirangura A. ATM nuclear localization in head and neck cancer cells is PPP2R2B-dependent. *Asian Biomedicine*, **4**: 3, 2010.
283. Dwyer J., Le Guelte A., Sumbal M., Carlotti A., Douguet L., Gutkind J.S., Grange P.A., Dupin N., and Gavard J. The human herpes virus 8 G-protein coupled receptor signaling pathway is linked to the loss of vascular integrity in human Kaposi Sarcoma. *Oncogene*, **30**:190-200, 2011.
284. Cervenka I., Wolf J., Masek J., Krejci P., Wilcox W.R., Kozubík A., Schulte G., Gutkind\* J.S., and Bryja\* V. Mitogen-activated protein kinases promote WNT/ $\beta$ -catenin signaling via phosphorylation of LRP6. *Mol. Cell. Biol.* **31**: 179-189, 2011.
285. Giulianelli S., Herschkowitz J.I., Patel V., Lamb C.A., Gutkind J.S., Molinolo A., Perou C.M., Lanari C. MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. *Breast Cancer Res. Treat.* **129**:49-67, 2011.
286. Bottino M.C., Cerliani J.P., Rojas P., Giulianelli S., Soldati R., Mondillo C., Gorostiaga M.A., Pignataro O.P., Calvo J.C., Gutkind J.S., Amornphimoltham P., Molinolo A.A., Lüthy I.A., and Lanari C. Classical membrane progesterone receptors in murine mammary carcinomas: agonistic effects of progestins and RU-486 mediating rapid non-genomic effects. *Breast Cancer Res. Treat.*, **126**:621-636, 2011.
287. Munge B.S., Coffey A.L., Doucette J.M., Somba B.K., Malhotra R., Patel V., Gutkind J.S., and Rusling J.F. Nanostructured Immunosensor for Attomolar Detection of Cancer Biomarker Interleukin-8 Using Massively Labeled Superparamagnetic Particles. *Angew Chem Int. Ed. Engl.*, **50**:7915-7918, 2011.
288. Chikkaveeraiah B.V., Mani V., Patel V., Gutkind J.S., and Rusling J.F. Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum. *Biosens. Bioelectron.*, **26**:4477-4483, 2011.
289. Maruyama T., Li J., Vaque J.P., Konkell J., Wang W., Zhang B., Zhang P., Zamarron B., Wu Y., Zhuang Y., Gutkind J.S., and Chen WJ. Control of the differentiation of regulatory T cells and T(H)17 cells by the DNA-binding inhibitor Id3. *Nature Immunol.*, **12**: 86-95, 2011.
290. Szabo R., Rasmussen A.L., Moyer A.B., Kosa P., Schafer J.M., Molinolo A.A., Gutkind J.S., and Bugge T.H. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. *Oncogene*, **30**: 2003-2016, 2011.

291. Sansing H.A., Sarkeshik A., Yates J.R., Patel V., Gutkind J.S., Yamada K.M., and Berrier A.L. Integrin  $\alpha\beta_1$ ,  $\alpha(v)\beta$ ,  $\alpha(6)\beta$  effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance. *Biochem. Biophys. Res. Commun.*, **406**: 171-176, 2011.
292. Cerliani J.P., Guillardoy T., Giulianelli S., Vaque J.P., Gutkind J.S., Vanzulli S.I., Martins R., Zeitlin E., Lamb C.A., and Lanari C. Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. *Cancer Res.* **71**:3720-3731, 2011.
293. Fujita M., Cha Y.R., Pham V.N., Sakurai A., Roman B.L., Gutkind J.S., Weinstein B.M. Assembly and patterning of the vascular network of the vertebrate hindbrain. *Development*, **138**:1705-1715, 2011.
294. Giulianelli S., Herschkowitz J.I., Patel V., Lamb C.A., Gutkind J.S., Molinolo A., Perou C.M., Lanari C. MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. *Breast Cancer Res Treat.*, **129**:49-67, 2011.
295. Bhirde AA, Liu G, Jin A, Iglesias-Bartolome R, Sousa AA, Leapman RD, Gutkind JS, Lee S, Chen X. Combining portable Raman probes with nanotubes for theranostic applications. *Theranostics*, **1**:310-321. 2011.
296. Sakurai A., Jian X., Lee C.J., Manavski Y., Chavakis E., Donaldson J., Randazzo P.A., and Gutkind J.S. PIP5 kinase and GEP100/Brag2 mediate anti-angiogenic signaling by Semaphorin 3E-Plexin-D1 through Arf6. *J. Biol. Chem.*, **286**:34335-343345, 2011.
297. Martin D., Galisteo R., Molinolo A.A., Wetzker R., Hirsch E., and Gutkind J.S. PI3Ky mediates Kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. *Cancer Cell*, **19**: 805-813, 2011.
298. Yagi H., Tan W., Dillenburg-Pilla P., Armando S., Amornphimoltham P., Simaan M., Weigert R., Molinolo A.A., Bouvier M., and Gutkind J.S. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. *Science Signaling*, **4**:ra60, 2011.
299. Patel V., Marsh C.A., Dorsam R.T., Masedunskas A., Amornphimoltham P., Nathan C.O., Singh B., Weigert R., Molinolo A.A., and Gutkind J.S. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. *Cancer Research*, **71**:7103-7112, 2011.
300. Bian Y., Hall B., Sun Z.J., Molinolo A., Chen W., Gutkind J.S., Waes C.V., and Kulkarni A.B. Loss of TGF- $\beta$  signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. *Oncogene*, **31**:3322-3332, 2012.
301. Berendsen A.D., Fisher L.W., Kilts T., Owens R.T., Robey P.G., Gutkind J.S., and Young M.F. Modulation of Canonical Wnt Signaling by the ECM Component, Biglycan. *Proc. Natl. Acad. Sci., USA*, **108**:17022-17027, 2011.
302. Leopoldino A.M., Squarize C.H., Garcia C.B., Almeida L.O., Pestana C.R., Polizello A.C., Uyemura S.A., Tajara E.H., Gutkind J.S., and Curti C. Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling. *Mol. Cell Biochem.*, **363**:65-74, 2012.
303. Degese M.S., Mendizabal J., Gandini N.A., Gutkind J.S., Molinolo A., Curino A.C., Coso O.M., and Facchinetti M.M. Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data. *Lung Cancer*, **77**:168-175, 2012.
304. Giulianelli S., Vaqué J.P., Soldati R., Wargon V., Vanzulli S.I., Martins R., Zeitlin E., Molinolo A.A., Helguero L.A., Lamb C.A., Gutkind J.S., and Lanari C. Estrogen receptors alpha mediate progestin induced mammary tumor growth interacting with progesterone receptors at the Cyclin D1/MYC promoters. *Cancer Research*, **72**:2416-2427, 2012.
305. Molinolo A.A., Marsh C., El Dinali M., Gangane N., Jennison K., Hewitt S., Patel V., Seiwert T.Y., and Gutkind J.S. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas. *Clin. Cancer Research*, **18**:2558-2568, 2012.

306. Vitale-Cross L., Molinolo A.A., Martin D., Younis R.H., Maruyama T., Patel P., Chen W., Schneider A., and Gutkind J.S. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. *Cancer Prevention Research*, **5**:562-573, 2012.
307. Krejci P., Aklian A., Kaucka M., Sevcikova E., Prochazkova J., Masek J.K., Mikolka P., Pospisilova T., Spoustova T., Weis M.A., Paznekas W., Wolf J.H., Gutkind J.S., Wilcox W.R., Kozubik A., Jabs E.W., Bryja V., and Balek L. Receptor tyrosine kinases activate canonical WNT/ $\beta$ -catenin signaling via MAP kinase/LRP6 pathway and direct  $\beta$ -catenin phosphorylation. *PLoS One.*, **7**:e35826, 2012.
308. Pan W., Pham V.N., Stratman A.N., Castranova D., Kamei M., Kidd K.R., Lo B.D., Shaw K.M., Torres-Vazquez J., Mikelis C.M., Gutkind J.S., Davis G.E., Weinstein B.M. CDP-diacylglycerol synthetase-controlled phosphoinositide availability limits VEGFA signaling and vascular morphogenesis. *Blood*, **120**: 489-498, 2012.
309. Bhirde A.A., Kapoor A., Liu G., Iglesias-Bartolome R., Jin A., Zhang G., Xing R., Lee S., Leapman R.D., Gutkind J.S., Chen X. Nuclear Mapping of Nanodrug Delivery Systems in Dynamic Cellular Environments. *ACS Nano*, **6**:4966-4972, 2012.
310. Tamburrino A., Molinolo A.A., Salerno P., Chernock R.D., Raffeld M., Xi L., Gutkind J.S., Moley J.F., Wells S.A. Jr, Santoro M. Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases. *Clin. Cancer Research*, **84**: 6249-6255, 2012.
311. Malhotra R., Patel V., Chikkaveeraiah B.V., Munge B.S., Cheong S.C., Zain R.B., Abraham M.T., Dey D.K., Gutkind J.S., and Rusling J.F. Ultrasensitive detection of cancer biomarkers in the clinic by use of a nanostructured microfluidic array. *Anal. Chem.*, **84**:6249-6255, 2012.
312. Gandini N.A., Fermento M.E., Salomón D.G., Blasco J., Patel V., Gutkind J.S., Molinolo A.A., Facchinetti M.M., Curino A.C. Nuclear localization of heme oxygenase-1 is associated with tumor progression of head and neck squamous cell carcinomas. *Exp. Mol. Pathol.*, **93**:237-245, 2012.
313. Dutzan N., Vernal R., Vaque J.P., García-Sesnich J., Hernandez M., Abusleme L., Dezerega A., Gutkind J.S., and Gamonal J. Interleukin-21 Expression and its Association with Pro-Inflammatory Cytokines in Untreated Chronic Periodontitis Patients. *J. Periodontol.*, **83**: 948-954, 2012.
314. Sun Z.J., Zhang L., Hall B., Bian Y., Gutkind J.S., and Kulkarni A. B. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. *Clin. Cancer Research* **18**:5304-5313, 2012.
315. Szabo R., Sales K.U., Kosa P., Shylo N., Godiksen S., Friis S., Hansen K., Gutkind J.S., Vogel L.K., Hummler E., Camerer E., and Bugge, T.H. Reduced prostatic (CAP1/PRSS8) activity eliminates HAI-1 and HAI-2 deficiency-associated developmental defects by preventing matrilysin activation. *PLoS Genetics*, **8**: e1002937, 2012.
316. Iglesias-Bartolome R., Patel V., Cotrim A., Leelahavanichkul K., Molinolo A.A., Mitchell J.B., and Gutkind J.S. mTOR inhibition protects from epithelial stem cell senescence and radiation-induced mucositis. *Cell Stem Cell*, **11**:401-414, 2012.
317. Almeida L.O., Goto R.N., Pestana C.R., Uyemura S.A., Gutkind J.S., Curti C., Leopoldino A.M. SET overexpression decreases cell detoxification efficiency: ALDH2 and GSTP1 are downregulated, DDR is impaired and DNA damage accumulates. *FEBS J.*, **279**:4615-4628, 2012.
318. Chow H.Y., Jubb A.M., Koch J.N., Jaffer Z.M., Stepanova D., Campbell D.A., Duron S.G., O'Farrell M., Cai Q., Klein-Szanto A.J., Gutkind J.S., Hoeflich K.P., and Chernoff J. p21-activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. *Cancer Research*, **72**:5966-5975, 2012.

319. Saito K., Matsumoto S., Yasui H., Devasahayam N., Subramanian S., Munasinghe J.P., Patel V., Gutkind J.S., Mitchell J.B., Krishna M.C. Longitudinal Imaging Studies of Tumor Microenvironment in Mice Treated with the mTOR Inhibitor Rapamycin. *PLoS One*, **7**(11):e49456, 2012.
320. Amornphimoltham P., Rechache K., Thompson J., Masedunskas A., Leelahavanichkul K., Patel V., Molinolo A., Gutkind J.S., and Weigert R. Rab25 regulates invasion and metastasis in head and neck cancer. *Clin. Cancer Research*, **19**:1375-1388, 2013.
321. Patel V., Martin D., Malhotra R., Marsh C.A., Doçi C.L., Veenstra T.D., Nathan C.A., Sinha U.K., Singh B., Molinolo A.A., Rusling J.F., and Gutkind J.S. DSG3 as a biomarker for the ultrasensitive detection of occult lymph node metastasis in oral cancer using nanostructured immunoarrays. *Oral Oncology*, **49**:93-101, 2013.
322. Hoeben A., Martin D., Clement P.M., and Gutkind J.S. Role of GAB1 in EGFR-induced signaling in head and neck squamous cell carcinoma. *Internatl. J. Cancer*, **132**:1042-1050, 2013.
323. Xie-Zukauskas H., Das J., Short B.L., Gutkind J.S., and Ray P.E. Heparin inhibits angiotensin II-induced vasoconstriction on isolated mouse mesenteric resistance arteries through Rho-A- and PKA-dependent pathways. *Vascul. Pharmacol.*, **58**:313-318, 2013.
324. Vaqué J.P., Dorsam R.T., Feng X., Iglesias-Bartolome R., Forsthoefel D.J., Chen Q., Debant A., Seeger M.A., Ksander B.R., Teramoto H., Gutkind J.S. A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing GPCR-initiated mitogenic signals. *Molecular Cell*, **49**:94-108, 2013.
325. Chen J.J., Mikelis C.M., Zhang Y., Gutkind J.S., and Zhang B. TRAIL induces apoptosis in oral squamous carcinoma cells - a crosstalk with oncogenic Ras regulated cell surface expression of death receptor 5. *Oncotarget*, **4**:206-217, 2013.
326. Alonso N., Fernandez N., Notcovich C., Monczor F., Simaan M., Baldi A., Gutkind J.S., Davio C., and Shayo C. Cross-Desensitization and Co-internalization of H1 and H2 Histamine Receptors Reveal New Insights into Histamine Signal Integration. *Mol. Pharmacol.*, **83**:1087-1098, 2013.
327. Mikelis C.M., Palmby T.R., Simaan M., Li W., Szabo R., Lyons R., Martin D., Yagi H., Fukuhara S., Chikumi H., Galisteo R., Mukouyama Y., Bugge T.H., and Gutkind J.S. PDZ-RhoGEF and LARG are essential for embryo development, and provide a link between thrombin and LPA receptors and Rho activation. *J. Biol. Chem.*, **288**:12232-12243, 2013.
328. Squarize C.H., Castilho R.M., Abrahao A.C., Molinolo A., Lingen M.W., and Gutkind J.S. PTEN deficiency contributes to the development and progression of head and neck cancer. *Neoplasia*, **15**:461-471, 2013.
329. Han G., Bian L., Li F., Cotrim A., Wang D., Lu J.B., Deng Y., Bird G., Sowers A., Mitchell J., Gutkind J.S., Zhao R., Raben D., Dijke P.T., Refaeli Y., Zhang Q., and Wang X.J. Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. *Nature Medicine*, **19**:421-428, 2013.
330. Patel S.J., Molinolo A.A., Gutkind J.S., and Crawford N.P. Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma. *PLoS One.*, **8**: e61848, 2013.
331. Coppock J.D., Wieking B.G., Molinolo A.A., Gutkind J.S., Miskimins W.K., and Lee J.H. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR Inhibition. *Neoplasia*, **15**:620-630, 2013.
332. Wang Y., Lu X., Zhu L., Shen Y., Chengedza S., Feng H., Wang L., Jung J.U., Gutkind J.S., and Feng P. The IKK $\epsilon$  kinase is crucial for viral G Protein-coupled receptor tumorigenesis, *Proc. Natl. Acad. Sci. U.S.A.*, **110**:11139-11144, 2013.
333. Wei J.S., Johansson P., Chen L., Song Y.K., Tolman C., Li S., Hurd L., Patidar R., Wen X., Badgett T.C., Cheuk A.T., Marshall J.C., Steeg P.S., Vaqué Díez J.P., Yu Y., Gutkind J.S., Khan J. Massively Parallel Sequencing Reveals an Accumulation of De Novo

- Mutations and an Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma. *PLoS One*, **8**: e77731, 2013.
334. Artamonov M.V., Momotani K., Stevenson A., Trentham D.R., Derewenda U., Derewenda Z.S., Read P.W., Gutkind J.S., and Somlyo A.V. Agonist-induced Ca<sup>2+</sup>-sensitization in smooth muscle: redundancy of RhoGEFs and response kinetics; a caged compound study. *J. Biol. Chem.*, **288**:34030-34040, 2013.
  335. Krause C.E., Otieno B.A., Latus A., Faria R.C., Patel V., Gutkind J.S., and Rusling J.F. Rapid microfluidic immunoassays of cancer biomarker proteins using disposable inkjet-printed gold nanoparticle arrays. *ChemistryOpen*, **2**:141-145, 2013.
  336. O'Hayre M., Vázquez-Prado J., Kufareva I., Stawiski E.W., Handel T., Seshagiri S., and Gutkind J.S. The emerging mutational landscape of G-proteins and G-protein-coupled receptors in cancer. (Analysis) *Nature Rev. Cancer*, **13**:412-424, 2013.
  337. Martin D., Nguyen Q., Molinolo A., and Gutkind J.S. Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene. *Oncogene*, **33**:2405-2412, 2014.
  338. Abrigo M., Alvarez R., Paparella M.L., Calb D., Bal de Kier Joffé E., Gutkind J.S., Raimondi A.R. Impairing squamous differentiation by Klf4 deletion is sufficient to initiate tongue carcinoma development upon K-Ras activation in mice. *Carcinogenesis*, **35**:662-669, 2014.
  339. Qi S., O'Hayre M., Gutkind J.S., and Hurley J.H. Structural and Biochemical Basis for Ubiquitin Ligase Recruitment by Arrestin-Related Domain-Containing Protein-3 (ARRDC3). *J. Biol. Chem.* **289**:4743-4752, 2014.
  340. Nudelman Z., Friedman M., Barasch D., Nemirovski A., Findler M., Pikovsky A., Gutkind J.S., Czerninski R. Levels of sirolimus in saliva and blood following mouthwash application. *Oral Dis.*, **20**:768-772, 2014.
  341. Manavski Y., Carmona G., Bennewitz K., Tang Z., Zhang F., Sakurai A., Zeiher A.M., Gutkind J.S., Li X., Kroll J., Dimmeler S., and Chavakis E. Brag2 differentially regulates  $\beta$ 1- and  $\beta$ 3-integrin-dependent adhesion in endothelial cells and is involved in developmental and pathological angiogenesis. *Basic. Res. Cardiol.*, **109**:404, 2014.
  342. Sales K.U., Friis S., Konkel J.E., Godiksen S., Hatakeyama M., Hansen K.K., Rogatto S.R., Szabo R., Vogel L.K., Chen W., Gutkind J.S., and Bugge T.H. Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis. *Oncogene*, **34**:346-356, 2014.
  343. Castellone M.D., Laukkanen M.O., Teramoto H., Bellelli R., Ali G., Fontanini G., Santoro M., and Gutkind J.S. Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma. *Oncogene*, **34**:1679-1687, 2014.
  344. Leelahavanichkul K., Amornphimoltham P., Molinolo A.A., Basile J.R., Koontongkaew S., and Gutkind J.S. A Role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis. *Mol. Oncology*, **8**:105-118, 2014.
  345. Adi A.H., Alturkmani H., Spock T., Yohannes P.W., Wargo S., Szabo E., Gutkind J.S., Van Waes C. Dermatomyositis paraneoplastic syndrome prior to symptomatic tonsillar squamous cell carcinoma: A case report. *Head Neck*. **37**: E1-3, 2014.
  346. Bhirde A.A., Chikkaveeraiah B.V., Srivatsan A., Niu G., Jin A.J., Kapoor A., Wang Z., Patel S., Patel V., Gorbach A.M., Leapman R.D., Gutkind J.S., Hight Walker A.R., Chen X. Targeted therapeutic nanotubes influence the viscoelasticity of cancer cells to overcome drug resistance. *ACS Nano.*, **8**:4177-4189, 2014.
  347. González F.E., Ortiz C., Reyes M., Dutzan N., Patel V., Pereda C., Gleisner M.A., López M.N., Gutkind J.S., and Salazar-Onfray F. Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells. *Immunology*, **142**:396-405, 2014.

348. Sobral L.M., Sousa L.O., Coletta R.D., Cabral H., Greene L.J., Tajara E.H., Gutkind J.S., Curti C., Leopoldino A.M. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models. *Mol. Cancer*, **13**:32 (1-13), 2014.
349. Xie X., Colberg-Poley A.M., Das J.R., Li J., Zhang A., Tang P., Jerebtsova M., Gutkind J.S., Ray P.E. The Basic Domain of HIV-Tat Transactivating Protein Is Essential for Its Targeting to Lipid Rafts and Regulating Fibroblast Growth Factor-2 Signaling in Podocytes Isolated from Children with HIV-1-Associated Nephropathy. *J. Am. Soc. Nephrol.*, **25**: 1800-1813, 2014.
350. Homolya L., Fu D., Sengupta P., Jarnik M., Gillet J.P., Vitale-Cross L., Gutkind J.S., Lippincott-Schwartz J., Arias I.M. LKB1/AMPK and PKA control ABCB11 trafficking and polarization in hepatocytes. *PLoS One*, **9**: e91921, 2014.
351. Prickett T.D., Zerlanko B.J., Hill V.K., Gartner J.J., Qutob N., Jiang J., Simaan M., Wunderlich J., Gutkind J.S., Rosenberg S.A., and Samuels Y. Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation. *J. Invest. Dermatol.*, **134**:2390-2398, 2014.
352. Smith J.P., Cooper T.K., McGovern C.O., Gilius E.L., Zhong Q., Liao J., Molinolo A.A., Gutkind J.S., and Matters G.L. Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice. *Pancreas*, **43**(7):1050-9, 2014.
353. Feng K., Degese M.S., Iglesias-Bartolome R., Vaque J.P., Molinolo A.A., Rodrigues M., Zaidi M.R., Ksander B.R., Merlino M., Sodhi A., Chen Q., and Gutkind J.S. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a Trio-regulated Rho GTPase signaling circuitry. *Cancer Cell*, **25**:831-845, 2014.
354. Wang Z., Martin D., Molinolo A.A., Patel V., Iglesias-Bartolome R., Degese M.S., Vitale-Cross L., Chen Q., and Gutkind J.S. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring *PIK3CA* and *RAS* mutations. *J. Natl. Cancer Inst.*, **106**(9) pii: dju215
355. Liu G., Yu F.X., Kim Y.C., Meng Z., Naipauer J., Looney D.J., Liu X., Gutkind J.S., Mesri E.A., and Guan K.L. Kaposi sarcoma-associated herpesvirus promotes tumorigenesis by modulating the Hippo pathway. *Oncogene*, **34**:3536-3546, 2014.
356. Luke J.J., Triozzi P.L., McKenna K.C., Van Meir E.G., Gershenwald J.E., Bastian B.C., Gutkind J.S., Bowcock A.M., Streicher H.Z., Patel P.M., Sato T., Sossman J.A., Sznol M., Welch J., Thurin M., Selig S., Flaherty K.T., and Carvajal R.D. Biology of advanced uveal melanoma and next steps for clinical therapeutics. *Pigment Cell Melanoma Res.* **7**:10696-10709 2014.
357. Qi S., O'Hayre M., Gutkind J.S., and Hurley J.H. Insights into  $\beta$ 2-Adrenergic Receptor Binding from Structures of the N-Terminal Lobe of ARRDC3. *Protein Science*, **23**:1708-1716, 2014.
358. Martin D., Abba M.C., Molinolo A.A., Vitale-Cross L., Wang Z., Zaida M., Delic N.C., Samuels Y., Lyons J.G., and Gutkind J.S. The head and neck cancer cell oncogenome: A platform for the development of precision molecular therapies. *Oncotarget* **5**:8906-8923, 2014.
359. Gan C.P., Patel V., Mikelis C.M., Zain R.B., Molinolo A.A., Abraham M.T., Teo S.H., Abdul Rahman Z.A., Gutkind J.S., Cheong S.C. Heterotrimeric G-protein alpha-12 ( $G\alpha_{12}$ ) subunit promotes oral cancer metastasis. *Oncotarget* **5**:9626-9640, 2014.
360. Williams K.A., Lee M., Hu Y., Andreas J., Patel S.J., Zhang S., Chines P., Elkahloun A., Chandrasekharappa S., Gutkind J.S., Molinolo A.A., Crawford N.P. A Systems Genetics Approach Identifies CXCL14, ITGAX, and LPCAT2 as Novel Aggressive Prostate Cancer Susceptibility Genes. *PLoS Genet.* **10**: e1004809, 2014.

361. Dillenburg-Pilla P., Patel V., Mikelis C.M., Zárate-Bladés C.R., Doçi C.L., Amornphimoltham P., Wang Z., Martin D., Leelahavanichkul K., Dorsam R.T., Masedunskas A., Weigert R., Molinolo A.A., Gutkind J.S. SDF-1/CXCL12 induces directional cell migration and spontaneous metastasis via a CXCR4/Gai/mTORC1 axis. *FASEB J.*, **29**:1056-1068, 2015.
362. Wang Z., Wang Y., Wang Z., Gutkind J.S., Wang Z., Wang F., Lu J., Niu G., Teng G., Chen X. Engineered Mesenchymal stem cells with enhanced tropism and paracrine secretion of cytokines and growth factors to treat traumatic brain injury. *Stem Cells*, **33**:456-467, 2015.
363. Deshapriya I.K., Stromer B.S., Pattammattel A., Kim C.S., Iglesias-Bartolome R., Gonzalez-Fajardo L., Patel V., Gutkind J.S., Lu X., Kumar C.V. Fluorescent, bioactive protein nanoparticles (prodots) for rapid, improved cellular uptake. *Bioconjug Chem.* **26**:396-404, 2015.
364. Nudelman Z., Findler M., Barasch D., Nemirovski A., Pikovsky A., Kirmayer D., Basheer M., Gutkind J.S., Friedman M., and Czerninski R. Levels of sirolimus in saliva and blood following oral topical sustained-release varnish delivery system application. *Cancer Chemother Pharmacol.*, **75**:969-74, 2015.
365. Degese M.S., Tanos T., Naipauer J., Gingerich T., Chiappe D., Echeverria P., LaMarre J., Gutkind J.S., and Coso O.A. An interplay between the p38 MAPK pathway and AUBPs regulate *c-fos* mRNA stability during mitogenic stimulation. *Biochem J.*, **467**:77-90, 2015.
366. Madera D., Vitale-Cross L., Martin D., Schneider A., Molinolo A.A., Gangane N., Carey T.E., McHugh J.B., Komarck C.M., Walline H.M., William Jr. W.N., Seethala R.R., Ferris R., and Gutkind J.S. Prevention of tumor growth driven by *PIK3CA* and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. *Cancer Prevention Res. (AACR)*, **8**:197-207, 2015.
367. Mikelis C.M., Simaan M., Ando K., Fukuhara S., Sakurai A., Amornphimoltham P., Masedunskas A., Weigert R., Chavakis T., Adams R., Offermanns S., Mochizuki N., Zheng Y., and Gutkind J.S. RhoA and ROCK mediate histamine-induced vascular leakage and anaphylactic shock. *Nature Commun.*, **6**:6725, 2015.
368. Doçi C.L., Mikelis C.M., Lionakis M.S., Molinolo A.A., and Gutkind J.S. Genetic identification of SEMA3F as an anti-lymphangiogenic metastasis suppressor gene in head and neck squamous carcinoma. *Cancer Research*, **75**:2937-2948, 2015.
369. Wang Z., Wang Y., Wang Z., Zhao J., Gutkind J.S., Srivatsan A., Zhang G., Liao H.S., Fu X., Jin A., Tong X., Niu G., and Chen X. Polymeric nanovehicle regulated spatiotemporal real-time imaging of the differentiation dynamics of transplanted neural stem cells after traumatic brain injury. *ACS Nano.*, **9**:6683-6692, 2015.
370. House C.D., Wang B.D., Ceniccola K., Williams R., Simaan M., Olender J., Patel V., Baptista-Hon D.T., Annunziata C.M., Gutkind J.S., Hales T.G., and Lee N.H. Voltage-gated Na<sup>+</sup> Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion via Persistent MAPK Signaling. *Sci. Rep.*, **5**:11541, 2015.
371. Iglesias-Bartolome R., Torres D., Marone R., Feng X., Martin D., Simaan M., Chen M., Weinstein L.S., Taylor S.S., Molinolo A.A., and Gutkind J.S. Inactivation of a Gas-PAK tumor suppressor pathway in skin stem cells initiates basal-cell carcinogenesis. *Nature Cell Biol.*, **17**:793-803, 2015.
372. O'Hayre M., Inoue A., Kufareva I., Wang Z., Mikelis C.M., Drummond R.A., Avino S., Finkel K., Kalim K.W., DiPasquale G., Guo F., Aoki J., Zheng Y., Lionakis M.S., Molinolo A.A., and Gutkind J.S. Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells. *Oncogene*, **35**:3771-80, 2015.
373. Yu G.T., Bu L.L., Huang C.F., Zhang W.F., Chen W.J., Gutkind J.S., Kulkarni A.B., Sun Z.J. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of

- CD47/SIRP $\alpha$  axis in HPV negative head and neck squamous cell carcinoma. *Oncotarget*, **6**:42067-42080, 2015.
374. Cimas F.J., Callejas-Valera J.L., Pascual-Serra R., García-Cano J., Garcia-Gil E., De la Cruz-Morcillo M.A., Ortega-Muelas M., Serrano-Oviedo L., Gutkind J.S., and Sánchez Prieto R. MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells. *Oncotarget*, **6**:44095-44107, 2015.
375. William W.N. Jr, Papadimitrakopoulou V., Lee J.J., Mao L., Cohen E.E., Lin H.Y., Gillenwater A.M., Martin J.W., Lingen M.W., Boyle J.O., Shin D.M., Vigneswaran N., Shinn N., Heymach J.V., Wistuba I.I., Tang X., Kim E.S., Saintigny P., Blair E.A., Meiller T., Gutkind J.S., Myers J., El-Naggar A., and Lippman S.M. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. *JAMA Oncol.*, **2**:209-216, 2016.
376. Wang F., Yang K., Wang Z., Ma Y., Gutkind J.S., Hida N., Niu G., and Tian J. Combined image guided monitoring the pharmacokinetics of rapamycin loaded human serum albumin nanoparticles with a split luciferase reporter. *Nanoscale*, **8**:3991-4000, 2016.
377. Yamaguchi K., Iglesias-Bartolomé R., Wang Z., Callejas-Valera J.L., Amornphimoltham P., Molinolo A.A., Cohen E.E., Califano J.A., Lippman S.M., Luo J., and Gutkind J.S. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers. *Oncotarget*, **7**:10696-10709, 2016.
378. Nohata N, Uchida Y, Stratman AN, Adams RH, Zheng Y, Weinstein BM, Mukouyama YS, Gutkind JS. Temporal-specific roles of Rac1 during vascular development and retinal angiogenesis. *Dev Biol.* **411**:183-194, 2016.
379. Zhu Z., Pang B., Iglesias-Bartolome R., Wu X., Hu L., Zhang C., Wang J., Gutkind J.S., and Wang S. Prevention of irradiation-induced salivary hypofunction by rapamycin in swine parotid glands. *Oncotarget*, **7**:20271-20281, 2016.
380. Das J.R., Gutkind J.S., and Ray P.E. Circulating Fibroblast Growth Factor-2, HIV-Tat, and Vascular Endothelial Cell Growth Factor-A in HIV-Infected Children with Renal Disease Activate Rho-A and Src in Cultured Renal Endothelial Cells. *PLoS One*, **11**: e0153837, 2016.
381. Hidayatullah Fadlullah M.Z., Chiang I.K., Dionne K.R., Yee P.S., Gan C.P., Sam K.K., Tiong K.H., Wen Ng A.K., Martin D., Lim K.P., Kallarakkal T.G., Wan Mustafa W.M., Lau S.H., Abraham M.T., Zain R.B., Abdul Rahman Z.A., Molinolo A., Patel V., Gutkind J.S., Tan A.C., and Cheong S.C. Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies. *Oncotarget* **7**:27802-27818, 2016.
382. Alonso N., Diaz Nebreda A., Monczor F., Gutkind J.S., Davio C., Fernandez N., Shayo C. PI3K pathway is involved in ERK signaling cascade activation by histamine H2R agonist in HEK293T cells. *Biochim. Biophys. Acta.* **1860**:1998-2007, 2016.
383. Geiger J.L., Bauman J.E., Gibson M.K., Gooding W.E., Varadarajan P., Kotsakis A., Martin D., Gutkind J.S., Hedberg M.L., Grandis J.R., and Argiris A. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. *Head Neck*, **38**:1759-1764, 2016.
384. Zhao Z.L., Zhang L., Huang C.F., Ma S.R., Bu L.L., Liu J.F., Yu G.T., Liu B., Gutkind J.S., Kulkarni A.B., Zhang W.F., and Sun Z.J. NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell. *Sci. Rep.* **25**:24704. doi: 10.1038/srep24704, 2016.
385. Arthofer E., Hot B., Petersen J., Strakova K., Jager S., Grundmann M., Kostenis E., Gutkind J.S., Schulte G. WNT stimulation dissociates a Frizzled 4 inactive state complex with G $\alpha$ 12/13. *Mol Pharmacol.* **90**:447-459, 2016.
386. Nohata N., Abba M.C., Gutkind J.S. Unraveling the oral cancer lncRNAome: Identification of novel lncRNAs associated with malignant progression and HPV infection. *Oral Oncol.* **59**:58-66, 2016.

387. Porat-Shliom N., Tietgens A.J., Van Itallie C.M., Vitale-Cross L., Jarnik M., Harding O.J., Anderson J.M., Gutkind J.S., Weigert R., Arias I.M. Liver kinase B1 regulates hepatocellular tight junction distribution and function in vivo. *Hepatology*, **64**:1317-1329, 2016.
388. Deng W.W., Mao L., Yu G.T., Bu L.L., Ma S.R., Liu B., Gutkind J.S., Kulkarni A.B., Zhang W.F., Sun Z.J. LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. *Oncoimmunology*. **5**(11): e1239005, 2016
389. Callejas-Valera J.L., Iglesias-Bartolome R., Amornphimoltham P., Palacios-Garcia J., Martin D., Califano J.A., Molinolo A.A., Gutkind J.S. mTOR inhibition prevents rapid-onset of carcinogen-induced malignancies in a novel inducible HPV-16 E6/E7 mouse model. *Carcinogenesis*. **37**:1014-1025, 2016.
390. Andradas C., Blasco-Benito S., Castillo-Lluva S., Dillenburg-Pilla P., Diez-Alarcia R., Juanes-García A., García-Taboada E., Hernando-Llorente R., Soriano J., Hamann S., Wenners A., Alkatout I., Klapper W., Rocken C., Bauer M., Arnold N., Quintanilla M., Megias D., Vicente-Manzanares M., Urigüen L., Gutkind J.S., Guzmán M., Pérez-Gómez E., and Sánchez C. Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. *Oncotarget*, **7**:47565-47575, 2016.
391. Sakurai A., Doçi C.L., and Gutkind J.S. Using Heterologous COS-7 Cells to Identify Semaphorin-Signaling Components. *Methods Mol. Biol.* **493**:163-170, 2017.
392. Carter H., Marty R., Hofree M., Gross A., Jensen J., Fisch K.M., Wu X., DeBoever C., Van Nostrand E.L., Song Y., Wheeler E., Kreisberg J.F., Lippman S.M., Yeo G., Gutkind J.S., Ideker T. Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. *Cancer Discovery*. **7**:410-423, 2017
393. Gaykalova D.A., Zizkova V., Guo T., Tiscareno I., Wei Y., Vatahalli R., Hennessey P.T., Ahn J., Danilova L., Khan Z., Bishop J.A., Gutkind J.S., Koch W.M., Westra W.H., Fertig E.J., Ochs M.F., Califano J.A. Integrative computational analysis of transcriptional and epigenetic alterations implicates DTX1 as a putative tumor suppressor gene in HNSCC. *Oncotarget*, **8**:15349-15363, 2017.
394. Doçi C.L., Mikelis C.M., Callejas-Valera J.L., Hansen K.H., Molinolo A.A., Inoue A., Offermanns S., and Gutkind J.S. Epidermal loss of Gαq confers a migratory and differentiation defect in keratinocytes. *PLOS One*, **12**: e0173692, 2017.
395. Cimas F.J., Callejas-Valera J.L., García-Olmo D.C., Hernández-Losa J., Melgar-Rojas P., Ruiz-Hidalgo M.J., Pascual-Serra R., Ortega-Muelas M., Roche O., Marcos P., Garcia-Gil E., Fernandez-Aroca D.M., Ramón Y Cajal S., Gutkind J.S., Sanchez-Prieto R. E1a is an exogenous in vivo tumour suppressor. *Cancer Lett.* **399**:74-81, 2017.
396. O'Hayre M., Eichel K., Avino S., Zhao X., Steffen D.J., Feng X., Kawakami K., Aoki J., Messer K., Sunahara R., Inoue A., von Zastrow M., and Gutkind J.S. Genetic evidence that β-arrestins are dispensable for the initiation of β2-adrenergic receptor signaling to ERK. *Science Signaling*, **10**(484) pii: eaal3395, 2017.
397. Raimondi F., Betts M.J., Lu Q., Inoue A., Gutkind J.S., and Russell R.B. Genetic variants affecting equivalent protein family positions reflect human diversity. *Sci. Rep.* **7**:12771-12777, 2017.
398. Guo T., Sakai A., Afsari B., Considine M., Danilova L., Favorov A.V., Yegnasubramanian S., Kelley D.Z., Flam E., Ha P.K., Khan Z., Wheelan S.J., Gutkind J.S., Fertig E.J., Gaykalova D.A., and Califano J. A Novel Functional Splice Variant of AKT3 Defined by Analysis of Alternative Splice Expression in HPV-Positive Oropharyngeal Cancers. *Cancer Res.* **77**:5248-5258, 2017.
399. Fukusumi T., Guo T., Sakai A., Ando M., Ren S., Haft S., Liu C., Amornphimoltham P., Gutkind J.S., and Califano J. The NOTCH4-HEY1 pathway induces epithelial mesenchymal transition in head and neck squamous cell carcinoma. *Clin Cancer Res.*

- 24**:619-633, 2018.
400. Zhao X., Deng P., Iglesias-Bartolome R., Amornphimoltham P., Steffen D.J., Jin Y., Molinolo A.A., de Castro L.F., Ovejero D., Yuan Q., Chen Q., Han X., Bai D., Taylor S.S., Yang Y., Collins M.T., and Gutkind J.S. Expression of an active Gas mutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance. *Proc Natl Acad Sci U.S.A.* **115**: E428-E437, 2017.
  401. Collar A.L., Swamydas M., O'Hayre M., Sajib M.S., Hoffman K.W., Singh S.P., Mourad A., Johnson M.D., Ferre E.M., Farber J.M., Lim J.K., Mikelis C.M., Gutkind J.S., Lionakis MS. The homozygous CX3CR1-M280 mutation impairs human monocyte survival. *JCI Insight*, **3**(3). pii: 95417, 2018. [ePub ahead of print]
  402. Lee B.K.B., Gan C.P., Chang J.K., Tan J.L., Fadlullah M.Z., Abdul Rahman Z.A., Prime S.S., Gutkind J.S., Liew C.S., Khang T.F., Tan A.C., Cheong S.C. GENIPAC: A Genomic Information Portal for Head and Neck Cancer Cell Systems. *J. Dent. Res.*, Mar 1, **1-8**, 2018.
  403. Martin D., Degese M.S., Vitale-Cross L., Iglesias-Bartolome R., Callejas Valera J.L., Wang Z. Feng X., Yeerna H., Vadmal V., Moroishi T., Thorne R., ZaidaM., Siegele B., Cheong S.C., Molinolo A.A., Samuels Y., Tamayo P., Guan K.L., Lippman SM., Lyons J.G., Gutkind J.S. Assembly and Activation of the Hippo Signalome by the FAT1 Tumor Suppressor. *Nature Comm.*, **9**:2372, 2018.
  404. Iglesias-Bartolome R., Uchiyama A., Molinolo A.A., Abusleme L., Brooks S.R., Callejas-Valera J.L., Edwards D., Doci C., Asselin-Labat M.-L., Onaitis M.W., Moutsopoulos N.M., Gutkind\* J.S., Morraso\* M.I. (\*Co-corresponding authors). Transcriptional signature primes human oral mucosa for rapid wound healing. *Sci. Transl. Med.*, **10**, eaap8798, 2018
  405. Ideno N. Yamaguchi H., Ghosh B., Gupta S., Okumura T., Delong Wood L., Singhi A. D., Gutkind J.S., Maitra A. GnasR201C induces pancreatic cystic neoplasms through suppression of YAP1 Signaling and Transcriptional Reprogramming. *Gastroenterology*. **155**(5):1593-1607.e12, 2018.
  406. Lee B.K.B., Gan C.P., Chang J.K., Tan J.L., Fadlullah M.Z., Abdul Rahman Z.A., Prime S.S., Gutkind J.S., Liew C.S., Khang T.F., Tan A.C., Cheong S.C.. GENIPAC: A Genomic Information Portal for Head and Neck Cancer Cell Systems. *J Dent Res*. **97**(8):909-916, 2018.
  407. Lubrano S., Comelli L., Piccirilli C., Marranci A., Dapporto F., Tantillo E., Gemignani F., Gutkind J.S., Salvetti A., Chiorino G., Cozza G., Chiariello M., Galli A., Poliseno L., Cervelli T.. Development of a yeast-based system to identify new hBRAFV600E functional interactors. *Oncogene*. **38**(8):1355-1366, 2019.
  408. Day T.A., Shirai K., O'Brien P.E., Matheus M.G., Godwin K., Sood A.J., Kompelli A., Vick J.A., Martin D., Vitale-Cross L., Callejas-Varela J.L., Wang Z., Wu X., Harismendy O., Molinolo A.A., Lippman S.M., Van Waes C., Szabo E., Gutkind J.S.. Inhibition of mTOR signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial. *Clin Cancer Res*. **25**(4):1156-1164, 2019.
  409. Cervantes-Villagrana R.D., Adame-García S.R., García-Jiménez I., Color-Aparicio V.M., Beltrán-Navarro Y.M., König G.M., Kostenis E., Reyes-Cruz G., Gutkind J.S., Vázquez-Prado J.. Gβγ signaling to the chemotactic effector P-REX1 and mammalian cell migration is directly regulated by Gα(q) and Gα(13) proteins. *J Biol Chem*. **11**;294(2):531-546, 2019.
  410. Adame-García S.R., Cervantes-Villagrana R.D., Orduña-Castillo L.B., Del Rio J.C., Gutkind J.S., Reyes-Cruz G., Taylor S.S., Vázquez-Prado J.. cAMP-dependent activation of the Rac guanine exchange factor P-REX1 by type I protein kinase A (PKA) regulatory subunits. *J Biol Chem*. **294**(7):2232-2246, 2019.
  411. Uchiyama A., Nayak S., Graf R., Cross M., Hasneen K., Gutkind J.S., Brooks S.R., Morasso M.I. SOX2 epidermal overexpression promotes cutaneous wound healing via

- activation of EGFR/MEK/ERK signaling mediated by EGFR ligands. *J Invest Dermatol*. pii: S0022-202X(19)30116-2, 2019.
412. Feng X., Arang N., Rigracciolo D.C., Lee J.S., Yeerna H., Wang Z., Lubrano S., Kishore A., Pachter J.A., König G.M., Maggiolini M., Kostenis E., Schlaepfer D.D., Tamayo P., Chen Q., Ruppin E., Gutkind J.S. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. *Cancer Cell*. **35**(3):457-472.e5, 2019.
  413. Bandekar S.J., Arang N., Tully E.S., Tang B.A., Barton B.L., Li S., Gutkind J.S., Tesmer J.J.G. Structure of the C-terminal guanine nucleotide exchange factor module of Trio in an autoinhibited conformation reveals its oncogenic potential. *Sci Signal*. **12**(569), 2019.
  414. Sahu A.D., Lee J., Wang Z., Zhang G., Iglesias-Bartolome R., Tian T., Wei Z., Miao B., Nair N.U., Ponomarova O., Friedman A.A., Amzallag A., Moll T., Kasumova G., Greninger P., Egan R.K., Damon L.J., Frederick D.T., Jerby-Arnon L., Wagner A., Cheng K., Park S.G., Robinson W., Gardner K., Boland G., Hannenhalli S., Herlyn M., Benes C., Flaherty K., Luo J., Gutkind J.S., Ruppin E. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. *Mol Syst Biol*. **15**(3):e8323, 2019.
  415. Annala S., Feng X., Shridhar N., Eryilmaz F., Patt J., Yang J., Pfeil E.M., Cervantes-Villagrana R.D., Inoue A., Häberlein F., Slodczyk T., Reher R., Kehraus S., Monteleone S., Schrage R., Heycke N., Rick U., Engel S., Pfeifer A., Kolb P., König G., Bünemann M., Tüting T., Vázquez-Prado J., Gutkind J.S., Gaffal E., Kostenis E. Direct targeting of Gα(q) and Gα(11) oncoproteins in cancer cells. *Sci Signal*. **12**(573), 2019.
  416. Wang Z., Feng X., Molinolo A.A., Martin D., Vitale-Cross L., Nohata N., Ando M., Wahba A., Amornphimoltham P., Wu X., Gilardi M., Allevato M., Wu V., Steffen D.J., Tofilon P., Sonenberg N., Califano J., Chen Q., Lippman S.M., Gutkind J.S. 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer. *Cancer Res*. **79**:1438-1450, 2019.
  417. Inoue A., Raimondi F., Kadji F.M.N., Singh G., Kishi T., Uwamizu A., Ono Y., Shinjo Y., Ishida S., Arang N., Kawakami K., Gutkind J.S., Aoki J., and Russel R.B. Illuminating G-Protein-Coupling Selectivity of GPCRs. *Cell*, **177**(7):1933-1947, 2019.
  418. Singh G., Inoue A., Gutkind J.S., Russell R.B., Raimondi F. PRECOG: PREdicting COupling probabilities of G-protein coupled receptors. *Nucleic Acids Res*. **47**(W1):W395-W401, 2019.
  419. Raimondi F., Inoue A., Kadji F.M.N., Shuai N., Gonzalez J.C., Singh G., de la Vega A.A., Sotillo R., Fischer B., Aoki J., Gutkind J.S., Russell R.B. Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm. *Oncogene*, **38**:6491-6506, 2019.
  420. Wu X., Yeerna H., Goto Y., Ando T., Wu V.H., Zhang X., Wang Z., Amornphimoltham P., Murphy A.N., Tamayo P., Chen Q., Lippman S.M., Gutkind J.S. Metformin inhibits progression of Head and Neck Squamous Cell Carcinoma by acting Directly on Carcinoma Initiating Cells. *Cancer Res*, **79**(17):4360-4370, 2019.
  421. Zahra F.T., Sajib M.S., Ichiyama Y., Akwii R.G., Tullar P.E., Cobos C., Minchew S.A., Doçi C.L., Zheng Y., Kubota Y., Gutkind J.S., Mikelis C.M. Endothelial RhoA GTPase is essential for in vitro endothelial functions but dispensable for physiological *in vivo* angiogenesis. *Sci Rep*. **9**(1):11666, 2019.
  422. Magen A., Das Sahu A., Lee J.S., Sharmin M., Lugo A., Gutkind J.S., Schäffer A.A., Ruppin E., Hannenhalli S. Beyond Synthetic Lethality: Charting the Landscape of Pairwise Gene Expression States Associated with Survival in Cancer. *Cell Rep*. **28**(4):938-948.e6, 2019.
  423. Wu V., Yeerna H., Nohata N., Chiou J., Harismendy O., Raimondi F., Inoue A., Russell R.B., Tamayo P., Gutkind J.S. Illuminating the Onco-GPCRome: Novel G protein-coupled

- receptor-driven oncocrine networks and targets for cancer immunotherapy. *J Biol Chem.* **294**(29):11062-11086, 2019.
424. Zainal N.S., Lee B.K.B., Wong Z.W., Chin I.S., Yee P.S., Gan C.P., Mun K.S., Rahman Z.A.A., Gutkind J.S., Patel V., Cheong S.C. Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance. *Cancer Biol Med.*, **16**(2):264-275, 2019.
425. Demb J., Yaseyyedi A., Liu L., Bustamante R., Earles A., Ghosh P., Gutkind J.S., Gawron A.J., Kaltenbach T.R., Martinez M.E., Gupta S. Metformin Is Associated With Reduced Odds for Colorectal Cancer Among Persons With Diabetes. *Clin Transl Gastroenterol.*, [Epub ahead of print], 2019.
426. Pedro M.P., Parra N.S., Gutkind J.S., Iglesias-Bartolome R. Activation of GPCR-Gai signaling increases keratinocyte proliferation and reduces differentiation, leading to epidermal hyperplasia. *J Invest Dermatol.* [Epub ahead of print], 2019.
427. Cash J.N., Urata S., Li S., Ravala S.K., Avramova L.V., Shost M.D., Gutkind J.S., Tesmer J.J.G., Cianfrocco M.A. Cryo-electron microscopy structure and analysis of the P-Rex1-Gβγ signaling scaffold. *Science Adv.*, **5**(10):eaax8855, 2019.
428. Miyauchi S., Sanders P.D., Guram K., Kim S.S., Paolini F., Venuti A., Cohen E.E.W., Gutkind J.S., Califano J.A., Sharabi A.B. HPV16 E5 Mediates Resistance to PD-L1 Blockade and can be targeted with Rimantadine in Head and Neck Cancer. *Cancer Res.* [Epub ahead of print], 2019
429. Wang Z., Wu V.H., Allevato M.M., Gilardi M., He Y., Callejas-Valera J.L., Vitale-Cross L., Martin D., Amornphimoltham P., Mcdermott J., Yung B.S., Goto Y., Molinolo A.A., Sharabi A.B., Cohen E.E.W. Chen Q., Lyons J.G., Alexandrov L.B., Gutkind J.S. Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. *Nature Comm.*, **10**(1):5546, 2019.
430. Dongre H., Rana N., Fromreide S., Rajthala S., Bøe Engelsen I., Paradis J., Gutkind J.S., Vintermyr O.K., Johannessen A.C., Bjørge L., Costea D.E. Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential. *Exp Cell Res.* **386**(1):111684, 2020.
431. Gulati S., Desai J., Palackdharry S.M., Morris J.C., Zhu Z., Jandarov R., Riaz M.K., Takiar V., Mierzwa M., Gutkind J.S., Molinolo A., Desai P.B., Sadraei N.H., Wise-Draper T.M. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. *Cancer*, **126**(2):354-362, 2020.

### Peer Reviewed Review Articles

432. Gutkind J.S. The pathway linking G protein-coupled receptors to divergent MAP kinase cascades. *J. Biol. Chem.*, Minireview 273:1839-42, 1998.
433. Gutkind J.S. Cell growth control by G protein-coupled receptors: From signal transduction to signal integration. *Oncogene*, **17**:1331-1342, 1998.
434. Winn D.M, Sandberg A.N., Horowitz A.M., Diehl S.R, Gutkind J.S., and Kleinman D.V. Reducing the burden of oral and pharyngeal cancers. *J. Calif. Dental Assoc.*, **26**:445-54, 1998.
435. Gutkind J.S. Regulation of Mitogen-Activated Protein Kinase signaling networks by G protein-coupled receptors. *Science STKE series*, Science's STKE -- Gutkind 2000 (40): 1re, 2000.
436. Marinissen M.J., and Gutkind J.S.: G Protein-coupled receptors and signaling networks: emerging paradigms. *Trends Pharmacol. Sci.*, **22**:368-76, 2001.
437. Pece S., and Gutkind J.S. E-cadherin and Hakai: signalling, remodeling or destruction? *Nature Cell Biol.*, **4**:E72-4, 2002.

438. Sodhi A., Montaner S., and Gutkind J.S. Viral hijacking of G-protein-coupled-receptor signalling networks. *Nature Rev. Mol. Cell. Biol.*, **12**:998-1012, 2004.
439. Vázquez-Prado J., Basile J., and Gutkind J.S. Modular Architecture and Novel Protein-Protein Interactions Regulating RGS-Containing RhoGEFs. *Methods in Enzymology*, **390**:259-285, 2004
440. Dennis P.A., Van Waes C., Gutkind J.S., Kellar K.J, Vinson C., Mukhin A.G., Spitz M.R., Bailey-Wilson J.E., Yeh G.C., Anderson L.M., and Wiest J.S. The Biology of Tobacco and Nicotine: Bench to Bedside. *Cancer Epidemiol. Biomarkers Prev.*, **14**:764-767, 2005.
441. Marinissen M.J. and Gutkind J.S. Scaffold proteins dictate Rho GTPase-signaling specificity. *Trends Biochem. Sci.*, **30**:423-426, 2005.
442. Castellone M.D., Teramoto H., and Gutkind J.S. COX-2 and colorectal cancer: The  $\beta$ -catenin connection. *Cancer Research*, **66**:11085-11088, 2006.
443. Gavard J. and Gutkind J.S. VE-cadherin takes a walk on the wild side. *Med Sci (Paris)*, **23**:119-121, 2007.
444. Turjanski A.G., Vaqué J.P., and Gutkind J.S. MAP Kinases and the Control of Nuclear Events. *Oncogene*, **26**:3240-3253, 2007.
445. Dorsam R. and Gutkind J.S. G protein-coupled receptors and cancer. *Nature Rev. Cancer*, **7**:79-94, 2007.
446. Gavard J. and Gutkind J.S. VE-Cadherin and Claudin-5: It takes two to tango. *Nature Cell Biology*, **10**:883-885, 2008.
447. Molinolo A.A., Amornphimoltham P., Squarize C.H., Castilho R.M., Patel V., and Gutkind J.S. Dysregulated molecular networks in head and neck carcinogenesis. *Oral Oncology*, **45**:324-334, 2009.
448. Gutkind J.S. and Offermanns S. A new G<sub>q</sub>-initiated MAPK signaling pathway in the heart. *Dev. Cell*, **16**:163-164, 2009.
449. Vitale-Cross L., Czerninski R., Amornphimoltham P., Patel V., Molinolo A.A., and Gutkind J.S. Chemical carcinogenesis models for evaluating molecular-targeted prevention and treatment of oral cancer. *Cancer Prevention Research*, **2**:419-422, 2009.
450. Martin D. and Gutkind J.S. Kaposi's sarcoma virally encoded, G-protein-coupled receptor: a paradigm for paracrine transformation. *Methods in Enzymology* **460**:125-150, 2009.
451. El-Naggar A.K., Kaye F.J., Shirazi Y., Gutkind J.S., Forastiere A.A. Meeting report--the NIDCR 2(nd) Salivary Gland Tumor Meeting. *Head Neck* **31**:1542-1543, 2009.
452. Martin D. and Gutkind J.S. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. *Oncogene* **27**, Suppl 2: S31-S42, 2009.
453. Rusling J.F., Kumar C.V., Gutkind J.S., and Patel V. Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. *Analyst*, **135**:2496-2511, 2010.
454. Iglesias-Bartolome R. and Gutkind J.S. Keeping the epidermal stem cell niche in shape. *Cell Stem Cell*, **7**:143-145, 2010.vastan
455. Iglesias-Bartolome R. and Gutkind J.S. Signaling circuitries and stem cell fate: To be or not to be. *Curr. Opin. Cell Biol.*, **23**:716-723, 2011.
456. Patel V., Iglesias-Bartolome R., Siegele B., Marsh C.A., Leelahavanichkul K., Molinolo A.A., and Gutkind J.S. Cellular systems for studying human oral squamous cell carcinomas. *Adv. Exp. Med. Biol.* **720**:27-38, 2011.
457. Sakurai A., Doci C., and Gutkind J.S. Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer. *Cell Research*, **22**:23-32, 2012.
458. Nguyen S.A., Walker D., Gillespie M.B., Gutkind J.S., and Day T.A. mTOR Inhibitors and its Role in the Treatment of Head and Neck Squamous Cell Carcinoma. *Curr. Treat Options Oncol.* **13**:71-81, 2012.
459. Wise-Draper T.M., Draper D.J., Gutkind J.S., Molinolo A.A., Wikenheiser-Brokamp K.A., and Wells S.I. Future directions and treatment strategies for head and neck squamous cell carcinomas. *Translational Research*, **160**:167-177, 2012.

460. Iglesias-Bartolome R. and Gutkind J.S. Exploiting the mTOR paradox for disease prevention. *Oncotarget*, **3**:1061-1063, 2012.
461. Montaner S. Kufareva I., Abagyan R., and Gutkind J.S. Molecular Mechanisms Deployed by Virally Encoded G Protein Coupled Receptors in Human Diseases. *Annual Review in Pharmacology and Toxicology*, **53**:17.1–17.24, 2013.
462. Castilho R., Squarize C., and Gutkind J.S. Exploiting PI3K/mTOR signaling to accelerate epithelial wound healing. *Oral Dis.*, **19**:551-558, 2013.
463. Iglesias-Bartolome R., Callejas-Valera J.L., and Gutkind J.S. Control of the epithelial stem cell epigenome: the shaping of epithelial stem cell identity. *Curr. Opin. Cell Biol.*, **25**:162-169, 2013.
464. Blelloch R., and Gutkind J.S. Epigenetics, noncoding RNAs, and cell signaling-crossroads in the regulation of cell fate decisions. *Curr. Opin. Cell Biol.* **25**:149-151, 2013.
465. Iglesias-Bartolome R., Martin D., and Gutkind J.S. Exploiting the head and neck cancer oncogenome: Widespread PI3K-mTOR pathway alterations and novel molecular targets. *Cancer Discovery*, **3**:722-725, 2013.
466. O'Hayre M., Degese M.S., and Gutkind J.S. Novel insights into G protein and G protein-coupled receptor signaling in cancer. *Curr. Opin. Cell Biol.*, **27**:126-135, 2014.
467. Feng X., Chen Q., and Gutkind J.S. Oncotargeting G proteins: The Hippo in the room. *Oncotarget* **5**:10997-10999, 2014.
468. Laukkanen M.O., Gutkind J.S., and Castellone M.D. Sonic Hedgehog in SCLC. *Aging* **7**:605-606, 2015.
469. Heldin C.H., Lu B., Evans R., and Gutkind J.S. Signals and Receptors. *Cold Spring Harb Perspect Biol.* **8**(4). pii: a005900, 2016.
470. Sakurai A., Doçi C.L., and Gutkind J.S. Using Heterologous COS-7 Cells to Identify Semaphorin-Signaling Components. *Methods Mol. Biol.* **1493**:163-170, 2017.
471. Nohata N., Goto Y., Gutkind J.S. Onco-GPCR signaling and dysregulated expression of microRNAs in human cancer. *J. Hum. Genet.* **62**:87-96, 2016.
472. Gutkind J.S and Bui J.D. The Next Frontier: Head and Neck Cancer Immunoprevention. *Cancer Prev. Res.* **10**:681-683, 2017.
473. Wang Z., Callejas Valera J., Zhao X. Chen Q., Gutkind J.S. mTOR co-targeting strategies for head and neck cancer therapy. *Cancer & Metastasis Rev.* **36**:491-502, 2017.
474. Nör J.E., Gutkind J.S. Head and Neck Cancer in the New Era of Precision Medicine. *J Dent Res.* **97**:601-602, 2018.
475. Gutkind J.S., Kostenis E. Arrestins as rheostats of GPCR signaling. *Nat. Rev. Mol. Cell Biol.*, **10**:1038, 2018.
476. Miyauchi S., Kim S.S., Pang J., Gold K.A., Gutkind J.S., Califano J., Mell L.K., Cohen E.E.W., Sharabi A.B. Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics. *Clin. Cancer Res.* pii: clincanres.0871.2019, 2019.
477. D'Silva N.J, Gutkind J.S. Oral Cancer: Integration of Studies for Diagnostic and Therapeutic Precision. *Adv Dent Res.* **30**(2):45-49, 2019.
478. Gutkind JS, Day TA, Lippman SM, Szabo E. Targeting mTOR in Head and Neck Cancer-Response. *Clin Cancer Res.* **25**(21):6555, 2019.

### **Book Chapters and Proceedings**

479. Castren E., Kurihara M., Gutkind J.S., and Saavedra J.M. Atrial natriuretic peptide receptors in thymus and spleen of young spontaneously hypertensive rats. In "Advances in Atrial Peptide Research". *ASH Symposium Series* volume II, 243-247, 1988.

480. Gutkind J.S., Kurihara M., Castren E., and Saavedra J.M. Atrial natriuretic peptide receptors in rat sympathetic ganglia: alterations in genetically hypertensive rats. In "Advances in Atrial Peptide Research", ASH Symposium Series volume II, 261-265, 1988.
481. Saavedra J.M., Castren E., Gutkind J.S., Kurihara M., and Nazarali A.J. Atrial natriuretic peptide and the autonomous nervous system. In "Atrial Natriuretic Peptides". Edited by R. Quirion and W.K. Samson. Boca Raton, Florida: CRC press, Inc., 209-220, 1989.
482. Saavedra J.M., Castren E., Gutkind J.S., and Nazarali A.J. Regulation of brain atrial natriuretic peptide and angiotensin receptors: Quantitative autoradiographic studies. *Internatl. Rev. of Neurobiol.*, **31**:257-296, 1989.
483. Gutkind J.S., Lacal P.M., Benhamou M., Siraganian R.P., and Robbins K.C. Evidence for protein-tyrosine kinase involvement in non-proliferative signal transduction. *Proc. II Internatl. Symp. on Oncogenes*, Spain, 101-132, 1991.
484. Siraganian R.P., Benhamou M., Stephan V., Gutkind J.S., and Robbins K.C. Tyrosine phosphorylation coupled to IgE receptor-mediated signal transduction and histamine release. Proc. XIV Internatl. Cong. Allergy and Clinical Immunology. In "Progress in Allergy and Clinical Immunology". Vol. 2. Edited by T. Miyamoto and M. Okuda. Toronto: Hogrefe and Huber, 354-359, 1992.
485. Gutkind J.S., Crespo P., Coso O., Kalinec G., and Xu N. Proliferative signaling through muscarinic acetylcholine receptors: a model for receptors coupled to heterotrimeric G Proteins. In "*Molecular Mechanisms of Muscarinic Acetylcholine Receptor Function*". Edited by Jurgen Wess. R.G Landes, Publisher, 103-141, 1995.
486. Gutkind J.S., Crespo P., Coso O., and Xu N. Signaling from heterotrimeric G proteins to MAP kinase involves  $\beta\gamma$  subunits acting on a *ras*-dependent pathway. In "The Molecular Basis of Cancer and Their Clinical Applications", Spanish Association for Cancer Research. Edited by J. C. Lacal, E. B. Olaetxea and R. Perona, pp. 137-146, 1996.
487. Gutkind J.S. and Vitale-Cross L. The pathway linking small GTP-binding proteins of the Rho Family to cytoskeletal components and novel signaling kinase cascades. *Seminars Cell. Dev. Biol.*, **7**:683-690, 1996.
488. Gutkind J.S., Vitale-Cross L., Crespo P., Xu N., Teramoto H., and Coso O.A. The pathway connecting G protein-coupled receptors to the nucleus involves small GTP-binding proteins acting on divergent MAP kinase cascades. In "Studies in Stomatology and Craniofacial Biology". Edited by M.M. Cohen, Jr., and B. Baum, IOS Press, pp. 39-57, 1997.
489. Gutkind J.S., Coso O.A., Xu N.  $G_{12}$  and  $G_{13}$   $\alpha$  subunits of heterotrimeric G proteins: A novel family of oncogenes. In "G Proteins, Receptors, and Disease". Edited by A.M. Spiegel. Humana Press, pp. 101-117, 1998.
490. Teramoto H. and Gutkind J.S. The pathway connecting muscarinic acetylcholine receptors to the nucleus involves small GTP-binding proteins. *Tanpakushitsu Kakusan Koso*, **43**:35-41 1998.
491. Gutkind J.S. Signaling from the Membrane to the Nucleus through Divergent MAP Kinase Cascades. In *Cell Signal Transduction, Implications for Drug Discovery*. IBC Library Series. Edited by Minden S.A. and Guttry P., pp. 39-60, 1998.
492. Chiariello M. and Gutkind J.S. Regulation of MAP Kinases by G Protein-Coupled Receptors. *Methods in Enzymology*, **345**:437-47, 2002.
493. Gutkind J.S. Editor, *Book on Signaling Networks and Cell Cycle Control*. Humana Press, 2000.
494. Fukuhara S., Marinissen M.J, Chiariello M., and Gutkind J.S. The pathway linking G protein-coupled receptors to the nucleus. In "*Signaling Networks and Cell Cycle Control*", Humana Press, Totowa, NJ, JS Gutkind Ed., 83-98, 2000.

495. Todd R., Gutkind J.S., Shillitoe E.J., and Wong D.T. Solid Tumors: Microarray analysis of oral cancers. In "*Microarrays and Cancer Research*", *Biotechniques Press*, Westborough, MA, J.A. Warrington, R. Todd, and D. Wong, Eds., 139-153, 2002.
496. Sodhi A., Montaner S., and Gutkind J.S. Molecular mechanisms of cancer. In "Signal Transduction and Human Disease". Edited by T. Finkel and J.S. Gutkind. Hoboken, NJ: John Wiley & Sons, pp 71-142, 2003.
497. Patel V., Leethanakul C., Amornphimoltham P., and Gutkind J.S. Squamous carcinomas of the head and neck: Novel genomic approaches. In "Head and Neck Cancer Emerging Perspectives". Edited by J.F. Ensley, J.S. Gutkind, J.R. Jacobs, and S.M. Lippman. Academic Press, San Diego, CA. pp. 509-522, 2003.
498. Rosenfeldt H., Marinissen M.J., and Gutkind J.S. G-protein-coupled receptors, cell transformation, and signal fidelity. In "Handbook of Cell Signaling", Edited by R.A. Bradshaw and E. A. Dennis. Elsevier Publishing Co., pp 589-599, 2003.
499. Crespo P. and Gutkind J.S. Activation of MAPKs by G Protein-Coupled Receptors. *Methods Mol. Biol.*, **250**:203-210, 2004.
500. Teramoto H. and Gutkind J.S. The Mitogen-Activated Protein Kinase family. In "Encyclopedia of Biological Chemistry". Edited by W.J. Lennarz and M.D. Lane Elsevier, Oxford, **2**:737-742, 2005.
501. Sodhi A. and Gutkind J.S. Endothelial cell transformation by the Kaposi's Sarcoma Herpesvirus. In "Encyclopedia of the Microvasculature", Edited by D. Shapro and J.A. Madri. Elsevier Science U.S.A., **147**:993-998, 2006.
502. Montaner S. and Gutkind J.S. The vascular endothelium as a target for hemorrhagic fever viruses. In "Encyclopedia of the Microvasculature", Edited by D. Shapro and J.A. Madri. Elsevier Science U.S.A., **102**:689, 694, 2006.
503. Marinissen M.J. and Gutkind J.S. Regulation of JNK by small GTPases. In "The JNK Signaling Pathway". Edited by A. Lin. Landes Bioscience, Georgetown, TX, **2**:13-28, 2006.
504. Gavard J. and Gutkind J.S. A Molecular Crosstalk between E-cadherin and EGFR Signaling Networks. In "Signaling Network in Cancer Therapy". Edited by J.D. Haley and W.J. Gullick. Humana Press Inc, **20**:139-154, 2008.
505. Palmby T.R., Rosenfeldt H., and Gutkind J.S. G Protein-coupled receptors, signal fidelity and cell transformation. In "The Handbook of Cell Signaling Second Edition", Edited by R. Bradshaw and E. Dennis. Elsevier Science U.S.A., **201**:1635-1648, 2009.
506. Amornphimoltham P., Patel V., Molinolo A., and Gutkind J.S. Head and Neck Cancer and the PI3K/Akt/mTOR signaling network: Novel Molecular Targeted Therapies. In "Signaling Pathways in Squamous Cancer." Edited by C. VanWaes and A. Glick. Springer Science & Business Media U.S.A., 407-430, 2011.
507. Chiariello M., Vaque J.P., and Gutkind J.S. Activation of MAPKs by G Protein-Coupled Receptors. *Methods Mol Biol.* **661**:137-50, 2010.
508. Vázquez-Prado J. and Gutkind J.S. RGS-RhoGEFs and other RGS multidomain proteins as Effector Molecules in GPCR-Dependent and GPCR-independent Cell Signaling. In "G Protein Coupled Receptors." Edited by S. Siehler and G. Milligan. Cambridge University Press, U.K., 160-186, 2011.
509. Leelahavanichkul K., Gutkind J.S. Oral and Pharyngeal Epithelial Keratinocyte Culture. *Methods in Molecular Biology*, **945**:67-79, 2013.
510. Castilho R.M., and Gutkind J.S. The Wnt  $\beta$ -catenin Signaling Circuitry in Head and Neck Cancer. In "*Molecular Determinants of Head and Neck Cancer*." Edited by E. Golemis and B. Burtneess. Springer Science, N.Y., **10**: 199-215, 2014.
511. Doçi, C.L. and Gutkind J.S. Targeting the PI3K-mTOR Signaling Circuitry in HPV-Associated Oral Malignancies: Novel Precision Molecular Therapies in "*Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer*." Edited by Daniel L. Miller and M. Sharon Stack. Springer International Publishing Switzerland, **7**: 153-170, 2016.

512. Gutkind J.S. and Sodhi A. Chapter 145 Molecular Genetics of Choroidal Melanoma *Ryan's Retina*, 6th Edition, **Volume 3**, Part 2, Section 2 Tumors of the Retina, Choroid, and Vitreous. pages 2533-2539. 2018.